Antibiotics for acute pyelonephritis in children by Strohmeier, Yvonne et al.
Cochrane
Library
 
Cochrane Database of Systematic Reviews
  Antibiotics for acute pyelonephritis in children (Review)  
  Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC  
  Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. 
Antibiotics for acute pyelonephritis in children. 
Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD003772. 
DOI: 10.1002/14651858.CD003772.pub4.
 
  www.cochranelibrary.com  
Antibiotics for acute pyelonephritis in children (Review) 
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
SUMMARY OF FINDINGS.............................................................................................................................................................................. 3
BACKGROUND.............................................................................................................................................................................................. 9
OBJECTIVES.................................................................................................................................................................................................. 9
METHODS..................................................................................................................................................................................................... 10
RESULTS........................................................................................................................................................................................................ 11
Figure 1.................................................................................................................................................................................................. 13
Figure 2.................................................................................................................................................................................................. 15
Figure 3.................................................................................................................................................................................................. 16
DISCUSSION.................................................................................................................................................................................................. 21
AUTHORS' CONCLUSIONS........................................................................................................................................................................... 23
ACKNOWLEDGEMENTS................................................................................................................................................................................ 23
REFERENCES................................................................................................................................................................................................ 24
CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 29
DATA AND ANALYSES.................................................................................................................................................................................... 63
Analysis 1.1. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 1 Time to fever resolution...................... 65
Analysis 1.2. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 2 Fever on Day 3..................................... 65
Analysis 1.3. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 3 Number with persistent UTI at 72
hours......................................................................................................................................................................................................
65
Analysis 1.4. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 4 Inflammatory markers at 72 hours....... 65
Analysis 1.5. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 5 Recurrent UTI within 6 months........... 66
Analysis 1.6. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 6 Persistent kidney damage at 6-12
months...................................................................................................................................................................................................
66
Analysis 1.7. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 7 Proportion of kidney parenchyma with
damage at 6 months.............................................................................................................................................................................
67
Analysis 1.8. Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 8 Kidney damage at 6 months (post hoc
subgroup analysis)................................................................................................................................................................................
67
Analysis 2.1. Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV therapy, Outcome 1 Persistent
bacteriuria aCer treatment...................................................................................................................................................................
68
Analysis 2.2. Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV therapy, Outcome 2 Recurrent UTI
within 6 months....................................................................................................................................................................................
68
Analysis 2.3. Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV therapy, Outcome 3 Persistent kidney
damage at 3-6 months.........................................................................................................................................................................
69
Analysis 2.4. Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV therapy, Outcome 4 Persistent kidney
damage at 3-6 months (post hoc subgroup analysis)........................................................................................................................
69
Analysis 2.5. Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV therapy, Outcome 5 Adverse eDects...... 70
Analysis 3.1. Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 1 Persistent
bacteriuria at 48 hours.........................................................................................................................................................................
71
Analysis 3.2. Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 2 Treatment
failure aCer 48 hours of therapy..........................................................................................................................................................
71
Analysis 3.3. Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 3 Recurrent
UTI within 1 month...............................................................................................................................................................................
71
Analysis 3.4. Comparison 3 Single dose parenteral therapy and oral therapy versus oral therapy alone, Outcome 4 Adverse
events.....................................................................................................................................................................................................
72
Analysis 4.1. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 1 Persistent
bacteriuria aCer 1-3 days of treatment...............................................................................................................................................
72
Analysis 4.2. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 2 Persistent
symptoms at end of 3 days of IV therapy............................................................................................................................................
73
Analysis 4.3. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 3 Persistent
bacteriuria at 1 week aCer treatment.................................................................................................................................................
73
Analysis 4.4. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 4 Reinfection at 1
month aCer completing treatment......................................................................................................................................................
73
Antibiotics for acute pyelonephritis in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 4.5. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 5 Hearing
impairment following treatment.........................................................................................................................................................
73
Analysis 4.6. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 6 Increase in serum
creatinine during treatment.................................................................................................................................................................
74
Analysis 4.7. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 7 Time to resolution
of fever...................................................................................................................................................................................................
74
Analysis 4.8. Comparison 4 DiDerent dosing regimens of aminoglycosides (daily versus 8 hourly), Outcome 8 Kidney
parenchymal damage at 3 months......................................................................................................................................................
74
Analysis 5.1. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 1 Persistent bacteriuria............... 75
Analysis 5.2. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 2 Recurrent UTI aCer end of
therapy...................................................................................................................................................................................................
75
Analysis 5.3. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 3 Persistent symptoms aCer end
of treatment..........................................................................................................................................................................................
76
Analysis 5.4. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 4 Number with fever for more
than 48 hours........................................................................................................................................................................................
76
Analysis 5.5. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 5 Recurrent bacteriuria at 4-6
weeks.....................................................................................................................................................................................................
76
Analysis 5.6. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 6 Recurrent symptomatic UTI at
4-6 weeks...............................................................................................................................................................................................
77
Analysis 5.7. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 7 Gastrointestinal adverse
events.....................................................................................................................................................................................................
77
Analysis 5.8. Comparison 5 Third generation cephalosporin versus other antibiotic, Outcome 8 Number discontinuing
treatment for adverse eDect................................................................................................................................................................
77
Analysis 6.1. Comparison 6 Cefepime versus ceCazidime, Outcome 1 Persistence or recurrence of initial pathogen.................... 78
Analysis 6.2. Comparison 6 Cefepime versus ceCazidime, Outcome 2 Infection with new pathogen at 4-6 weeks........................ 79
Analysis 6.3. Comparison 6 Cefepime versus ceCazidime, Outcome 3 Unsatisfactory clinical response........................................ 79
Analysis 6.4. Comparison 6 Cefepime versus ceCazidime, Outcome 4 Adverse eDects.................................................................... 79
Analysis 7.1. Comparison 7 CeCriaxone versus cefotaxime, Outcome 1 Persistent bacteriuria at 48 hours.................................... 81
Analysis 7.2. Comparison 7 CeCriaxone versus cefotaxime, Outcome 2 Bacteriuria 10 days aCer end of treatment...................... 81
Analysis 7.3. Comparison 7 CeCriaxone versus cefotaxime, Outcome 3 UTI at 1 month aCer therapy............................................ 81
Analysis 7.4. Comparison 7 CeCriaxone versus cefotaxime, Outcome 4 Adverse events.................................................................. 81
Analysis 8.1. Comparison 8 Isepamicin versus amikacin, Outcome 1 Persistent bacteriuria........................................................... 82
Analysis 9.1. Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 1 Recurrent UTI within 1 month aCer ceasing
therapy...................................................................................................................................................................................................
83
Analysis 9.2. Comparison 9 10 days versus 42 days of oral sulfafurazole, Outcome 2 Recurrent UTI at 1-12 months aCer
completing therapy...............................................................................................................................................................................
83
Analysis 10.1. Comparison 10 Single dose of parenteral antibiotic versus 7-10 days oral therapy, Outcome 1 Persistent
bacteriuria 1-2 days aCer treatment....................................................................................................................................................
83
Analysis 10.2. Comparison 10 Single dose of parenteral antibiotic versus 7-10 days oral therapy, Outcome 2 UTI relapse or
reinfection within 6 weeks...................................................................................................................................................................
84
Analysis 11.1. Comparison 11 3 weeks versus 2 weeks, Outcome 1 Persistence/recurrence of bacteriuria.................................... 84
Analysis 11.2. Comparison 11 3 weeks versus 2 weeks, Outcome 2 Recurrence of clinical UTI....................................................... 84
Analysis 12.1. Comparison 12 Suppositories versus oral ampicillin, Outcome 1 Persistence of clinical symptoms........................ 85
Analysis 12.2. Comparison 12 Suppositories versus oral ampicillin, Outcome 2 Persistence of bacteriuria................................... 85
ADDITIONAL TABLES.................................................................................................................................................................................... 85
APPENDICES................................................................................................................................................................................................. 89
WHAT'S NEW................................................................................................................................................................................................. 91
HISTORY........................................................................................................................................................................................................ 91
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 92
DECLARATIONS OF INTEREST..................................................................................................................................................................... 92
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 92
NOTES........................................................................................................................................................................................................... 92
INDEX TERMS............................................................................................................................................................................................... 92
Antibiotics for acute pyelonephritis in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ii
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
[Intervention Review]
Antibiotics for acute pyelonephritis in children
Yvonne Strohmeier1, Elisabeth M Hodson2,3, Narelle S Willis3,4, Angela C Webster3,4,5, Jonathan C Craig3,4
1Westmead Clinical School, University of Sydney, Westmead, Australia. 2Centre for Kidney Research, The Children's Hospital at
Westmead, Westmead, Australia. 3Sydney School of Public Health, The University of Sydney, Sydney, Australia. 4Cochrane Renal Group,
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia. 5Centre for Transplant and Renal Research,
Westmead Millennium Institute, The University of Sydney at Westmead, Westmead, Australia
Contact address: Elisabeth M Hodson, Centre for Kidney Research, The Children's Hospital at Westmead, Locked Bag 4001, Westmead,
NSW, 2145, Australia. elisabeth.hodson@health.nsw.gov.au.
Editorial group: Cochrane Kidney and Transplant Group
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 7, 2014.
Citation: Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database of
Systematic Reviews 2014, Issue 7. Art. No.: CD003772. DOI: 10.1002/14651858.CD003772.pub4.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Urinary tract infection (UTI) is one of the most common bacterial infections in infants. The most severe form of UTI is acute pyelonephritis,
which results in significant acute morbidity and may cause permanent kidney damage. There remains uncertainty regarding the optimum
antibiotic regimen, route of administration and duration of treatment. This is an update of a review that was first published in 2003 and
updated in 2005 and 2007.
Objectives
To evaluate the benefits and harms of antibiotics used to treat children with acute pyelonephritis. The aspects of therapy considered were
1) diDerent antibiotics, 2) diDerent dosing regimens of the same antibiotic, 3) diDerent duration of treatment, and 4) diDerent routes of
administration.
Search methods
We searched the Cochrane Renal Group's Specialised Register, CENTRAL, MEDLINE, EMBASE, reference lists of articles and conference
proceedings without language restriction to 10 April 2014.
Selection criteria
Randomised and quasi-randomised controlled trials comparing diDerent antibiotic agents, routes, frequencies or durations of therapy in
children aged 0 to 18 years with proven UTI and acute pyelonephritis were selected.
Data collection and analysis
Four authors independently assessed study quality and extracted data. Statistical analyses were performed using the random-eDects
model and the results expressed as risk ratio (RR) for dichotomous outcomes or mean diDerence (MD) for continuous data with 95%
confidence intervals (CI).
Main results
This updated review included 27 studies (4452 children). This update included evidence from three new studies, and following re-
evaluation, a previously excluded study was included because it now met our inclusion criteria.
Risk of bias was assessed as low for sequence generation (12 studies), allocation concealment (six studies), blinding of outcome assessors
(17 studies), incomplete outcome reporting (19 studies) and selective outcome reporting (13 studies). No study was blinded for participants
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or investigators. The 27 included studies evaluated 12 diDerent comparisons. No significant diDerences were found in duration of fever (2
studies, 808 children: MD 2.05 hours, 95% CI -0.84 to 4.94), persistent UTI at 72 hours aCer commencing therapy (2 studies, 542 children:
RR 1.10, 95% CI 0.07 to 17.41) or persistent kidney damage at six to 12 months (4 studies, 943 children: RR 0.82, 95% CI 0.59 to 1.12)
between oral antibiotic therapy (10 to 14 days) and intravenous (IV) therapy (3 days) followed by oral therapy (10 days). Similarly, no
significant diDerences in persistent bacteriuria at the end of treatment (4 studies, 305 children: RR 0.78, 95% CI 0.24 to 2.55) or persistent
kidney damage (4 studies, 726 children: RR 1.01, 95% CI 0.80 to 1.29) were found between IV therapy (three to four days) followed by oral
therapy and IV therapy (seven to 14 days). No significant diDerences in eDicacy were found between daily and thrice daily administration
of aminoglycosides (1 study, 179 children, persistent clinical symptoms at three days: RR 1.98, 95% CI 0.37 to 10.53). Adverse events were
mild and uncommon and rarely resulted in discontinuation of treatment.
Authors' conclusions
This updated review increases the body of evidence that oral antibiotics alone are as eDective as a short course (three to four days) of IV
antibiotics followed by oral therapy for a total treatment duration of 10 to 14 days for the treatment of acute pyelonephritis in children.
When IV antibiotics are given, a short course (two to four days) of IV therapy followed by oral therapy is as eDective as a longer course
(seven to 10 days) of IV therapy. If IV therapy with aminoglycosides is chosen, single daily dosing is safe and eDective. InsuDicient data are
available to extrapolate these findings to children aged less than one month of age or to children with dilating vesicoureteric reflux (grades
III-V). Further studies are required to determine the optimal total duration of antibiotic therapy required for acute pyelonephritis.
P L A I N   L A N G U A G E   S U M M A R Y
Are oral antibiotics as e4ective as a combination of injected and oral antibiotics for kidney infections in children?
Acute pyelonephritis refers to infection of the kidneys and is the most severe form of urinary tract infection (UTI). Acute pyelonephritis
causes high fever, vomiting, stomach pain, irritability and poor feeding in infants.
We wanted to find out if oral antibiotics were as eDective as combined oral and injected antibiotics to treat children for kidney infection.
This review updates our previous investigations published in 2003, 2005 and 2007. This review included evidence from 27 studies that
involved 4452 children. The last literature search date was April 2014. This update included evidence from three new studies and from one
study that was previously excluded.
Review results suggested that children aged over one month with acute pyelonephritis can be treated eDectively with oral antibiotics
(cefixime, ceCibuten or amoxicillin/clavulanic acid) or with short courses (two to four days) of intravenous (IV) therapy followed by oral
therapy. If IV therapy with aminoglycosides is needed, single daily dosing is safe and eDective.
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Summary of findings for the main comparison.   Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children
Oral versus IV followed by oral (11 days) therapy for acute pyelonephritis in children
Patient or population: children with acute pyelonephritis
Intervention: oral versus IV followed by oral (11 days) therapy
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Oral IV followed by oral (11
days) therapy
Relative ef-
fect
(95% CI)
No of partic-
ipants (stud-
ies)
Quality of the
evidence
(GRADE)
Comments
Time to fever resolution (hours)   The mean time to fever
resolution (hours) in the
intervention groups was
2.05 higher (0.84 lower
to 4.94 higher)
  808 (2) ⊕⊕⊕⊝
moderate1
 
Study population
224 per 1000 184 per 1000
(132 to 251)
Moderate
Renal parenchymal damage at 6 to 12 months: all
included children with acute pyelonephritis
DMSA scans
Follow-up: 6 to 12 months
313 per 1000 257 per 1000
(185 to 351)
RR 0.82 
(0.59 to 1.12)
943 (4) ⊕⊕⊕⊝
moderate2
 
Study population
320 per 1000 253 per 1000
(195 to 330)
Moderate
Renal parenchymal damage at 6 to 12 months:
children with renal parenchymal damage on ini-
tial DMSA
Follow-up: 6 to 12 months
382 per 1000 302 per 1000
(233 to 393)
RR 0.79 
(0.61 to 1.03)
681 (4) ⊕⊕⊕⊝
moderate3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Wide confidence intervals due to large standard deviations around the mean durations of fever
2 Large number of patients excluded because of lack of follow-up DMSA scans
3 No explanation was provided
 
 
Summary of findings 2.   Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children
Short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy for acute pyelonephritis in children
Patient or population: children with acute pyelonephritis
Intervention: short duration (3 to 4 days) versus long duration (7 to 14 days) IV therapy
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding
risk
Outcomes
Short duration (3 to 4 days) Long duration
(7 to 14 days) IV
therapy
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
38 per 1000 30 per 1000
(9 to 98)
Moderate
Persistent bacteriuria after treatment
0 per 1000 0 per 1000
(0 to 0)
RR 0.78 
(0.24 to 2.55)
305 (4) ⊕⊕⊝⊝
low1,2
 
Study populationRecurrent UTI within 6 months
59 per 1000 57 per 1000
(34 to 95)
RR 0.97 
(0.58 to 1.62)
993 (5) ⊕⊕⊕⊝
moderate1
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Moderate
56 per 1000 54 per 1000
(32 to 91)
Study population
246 per 1000 249 per 1000
(197 to 318)
Moderate
Persistent renal damage at 3 to 6
months: all included children with acute
pyelonephritis
257 per 1000 260 per 1000
(206 to 332)
RR 1.01 
(0.8 to 1.29)
726 (4) ⊕⊕⊕⊝
moderate1,3
 
Study population
357 per 1000 393 per 1000
(300 to 518)
Moderate
Persistent renal damage at 3 to 6 months:
children with initial renal parenchymal
damage on initial DMSA scan
Follow-up: 6-12 months
327 per 1000 360 per 1000
(275 to 474)
RR 1.1 
(0.84 to 1.45)
315 (3) ⊕⊕⊕⊝
moderate1,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unclear or inadequate allocation concealment
2 Small number of patients and events leading to wide confidence intervals
3 In several studies, more than 10% patients lost to follow-up or did not have follow-up DMSA scans
 
 
Summary of findings 3.   Di4erent dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children
Different dosing regimens of aminoglycosides (daily versus 8 hourly) for acute pyelonephritis in children
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Patient or population: children with acute pyelonephritis
Intervention: different dosing regimens of aminoglycosides (daily versus 8 hourly)
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Daily dose 8 hourly dose
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
9 per 1000 10 per 1000
(1 to 67)
Moderate
Persistent bacteriuria after 1
to 3 days of treatment
0 per 1000 0 per 1000
(0 to 0)
RR 1.05 
(0.15 to 7.27)
435 (3) ⊕⊕⊝⊝
low1,2
 
Study population
0 per 1000 0 per 1000
(0 to 0)
Moderate
Hearing impairment follow-
ing treatment
0 per 1000 0 per 1000
(0 to 0)
RR 2.83 
(0.33 to 24.56)
271 (3) ⊕⊕⊝⊝
low1,2
 
Study population
25 per 1000 19 per 1000
(5 to 70)
Moderate
Increase in serum creatinine
during treatment
25 per 1000 19 per 1000
(5 to 70)
RR 0.75 
(0.2 to 2.82)
419 (3) ⊕⊕⊝⊝
low1,2
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
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High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unclear allocation concealment in two of three studies
2 Few events resulting in wide confidence intervals
 
 
Summary of findings 4.   Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children
Agent: Third generation cephalosporin versus other antibiotic for acute pyelonephritis in children
Patient or population: children with acute pyelonephritis
Intervention: third generation cephalosporin versus other antibiotic
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Antibiotic Third generation
cephalosporin
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
34 per 1000 81 per 1000
(33 to 199)
Moderate
Persistent bacteriuria
0 per 1000 0 per 1000
(0 to 0)
RR 2.41 
(0.98 to 5.93)
439 (3) ⊕⊕⊝⊝
low1,2
 
Study population
18 per 1000 22 per 1000
(6 to 87)
Moderate
Recurrent UTI after
end of therapy
8 per 1000 10 per 1000
(3 to 38)
RR 1.23 
(0.32 to 4.74)
491 (4) ⊕⊕⊝⊝
low1,2
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Study population
104 per 1000 29 per 1000
(14 to 64)
Moderate
Persistent symptoms
after end of treat-
ment
0 per 1000 0 per 1000
(0 to 0)
RR 0.28 
(0.13 to 0.62)
471 (3) ⊕⊕⊝⊝
low1,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unclear allocation in several studies
2 Few events leading to imprecision
3 Meta-analysis dominated by single trial and results inconsistent with bacteriologic results
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B A C K G R O U N D
Description of the condition
The urinary tract is a common site of bacterial infection in infants
and young children. Pooled prevalence data demonstrate that
approximately 7% of girls and boys are diagnosed with at least
one urinary tract infection (UTI) by the age of 19 years (Shaikh
2008). Girls are more susceptible to UTIs than boys aCer the first
six months of life with a prevalence of 11% in girls and 4% in
boys (Brkic 2010). UTI is defined by the presence of bacteria in
urine (bacteriuria), which when cultured is measured in colony
forming units/mL (CFU/mL) of uncentrifuged urine. The diagnosis
of UTI in children is generally confirmed by the pure growth of a
bacteria of greater than 103 CFU/mL from a suprapubic aspirate,
104 CFU/mL from a bladder catheter specimen and 105 CFU/mL
from non-invasive collection methods (clean catch and urinary bag
specimens) (Bhat 2011).
UTIs can be clinically grouped into asymptomatic bacteriuria,
cystitis and acute pyelonephritis.
• Asymptomatic bacteriuria is the presence of bacteriuria without
clinical signs and symptoms.• Cystitis is a UTI limited to the urethra and bladder and is seen
most commonly in girls over two years of age. It presents
with localising symptoms of dysuria (pain when passing
urine), frequency, urgency, cloudy urine and lower abdominal
discomfort. Pyuria (white cells in the urine) and haematuria
(blood in the urine) may also be found.• Acute pyelonephritis refers to infection of the kidneys, and
is the most severe form of UTI in children. Clinically, this is
associated with systemic features such as high fever, malaise,
vomiting, abdominal and loin pain and tenderness, poor feeding
and irritability in infants. Together with urine culture, diagnosis
may be assisted by imaging using technetium 99m labelled
dimercaptosuccinic acid (DMSA) renal scan and markers of
inflammation in the blood such as erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP).• Acute pyelonephritis is associated with significant short-
term morbidity, including shock and septicaemia, especially
in infants. Acute kidney parenchymal injury has been
demonstrated on DMSA scan in about 60% of children
shortly aCer UTI diagnosis (Shaikh 2010). Permanent kidney
damage may occur following acute pyelonephritis and is more
frequent in children who have multiple episodes or who
have vesicoureteric reflux (VUR) (Shaikh 2010; Smellie 1985).
Serial DMSA scans of children aCer a first episode of acute
pyelonephritis show that 15% of children with acute changes
on DMSA scans have permanent kidney scarring at follow up
(Shaikh 2010). However, the long term significance of kidney
damage following acute pyelonephritis is debatable. In children
with previously normal kidneys, the amount of damage is small
and unlikely to cause disease (Salo 2011; ToDolo 2012).
Description of the intervention
A wide variety of antibiotic agents have been used to treat acute
pyelonephritis in children. Antibiotics that have been used include
aminoglycosides, cephalosporins, penicillins and trimethoprim/
sulphamethoxazole (TMP/SMX). Historically, children who are
judged by clinicians to be in poor general condition are given
parenteral antibiotics and those who appear less sick have
been given oral antibiotics, without clarity whether one route of
administration is superior. An antibiotic course of seven to 14
days is generally recommended although the optimal duration
of therapy is not known. Shorter courses may be associated
with treatment failure while longer courses may unnecessarily
expose children to the adverse eDects of treatment. This review
evaluated antibiotic therapies used to treat acute pyelonephritis,
with consideration of diDerent antibiotic agents, diDerent dosing
regimens of the same antibiotic, diDerent durations of treatment
and diDerent routes of administration.
How the intervention might work
Antibiotics work in the treatment of acute pyelonephritis by
eliminating bacterial infection in the urinary tract. The purpose of
antibiotic therapy is to eradicate and prevent progressive infection
and its consequences, including shock and septicaemia, reduce
acute kidney injury and resolve the acute clinical symptoms
of infection. The eDicacy of treatment depends on using the
antibiotic(s) to which the bacteria is sensitive. While the results of
antibiotic sensitivity testing are pending, initial treatment is chosen
on an empiric basis to cover the most likely cause of infection.
Why it is important to do this review
Acute pyelonephritis is a common serious infection in children.
Nonetheless, there remains no consensus on the most eDective
antibiotic regimen for the treatment of acute pyelonephritis. There
is also uncertainty regarding the optimal route of administration
of antibiotic therapy. Previously, most authorities recommended
commencing antibiotic therapy by the parenteral route. The most
recent guidelines however recommend initial treatment with oral
antibiotics for children older than two months (AAP 2011) or
three months of age (NICE 2007) unless children are considered
to be too unwell or unable to take oral antibiotics. This is
advantageous because oral therapy is more convenient and does
not require hospital admission, thereby reducing costs. There
is further uncertainty about the optimal duration of antibiotic
therapy. Currently, the recommended duration of therapy varies
from seven to 14 days.
This review update was necessary to provide additional
information about the optimum antibiotic regimens, route of
administration and duration of treatment for acute pyelonephritis
in children and about adverse eDects of treatment.
O B J E C T I V E S
To evaluate the benefits and harms of antibiotics used to
treat children with acute pyelonephritis. The aspects of therapy
considered were:
1. diDerent antibiotics
2. diDerent dosing regimens of the same antibiotic
3. diDerent duration of treatment
4. diDerent routes of administration.
Antibiotics for acute pyelonephritis in children (Review)
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M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in
which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) in which antibiotics were used in the treatment of
children (birth to 18 years) with acute pyelonephritis were included.
Where studies included both children with acute pyelonephritis
and those with cystitis, these were included if data for participants
with acute pyelonephritis could be extracted separately; otherwise,
these studies were excluded.
Types of participants
Inclusion criteria
Children from birth to 18 years with acute pyelonephritis treated
either in hospital or as outpatients with antibiotics were included.
For this review, the diagnosis of acute pyelonephritis required
UTI (as specified in the included studies but generally requiring
a bacterial growth on urine culture of more than 105 CFU/mL or
108 CFU/L) with at least one symptom or sign of systemic illness
such as fever, loin pain or toxicity and additional diagnostic criteria
as defined by the authors of the included studies. Children with
previously diagnosed urinary tract abnormalities including VUR or
previous UTI could be included.
Exclusion criteria
Patients considered to have asymptomatic bacteriuria or cystitis
(UTI as defined in Inclusions with no symptom or sign of systemic
illness) were excluded.
Types of interventions• DiDerent antibiotic agents• IV antibiotic versus oral antibiotic• DiDerent doses or duration or both of the same antibiotic• Antibiotic versus placebo, no therapy or alternative non-
antibiotic therapy.
Types of outcome measures
Primary outcomes
Short-term outcome measures.
• Duration of fever• Persistent symptoms (e.g. UTI at 72 hours; inflammatory
markers at 72 hours (ESR, WCC, CRP)• Acute kidney parenchymal damage on DMSA scan• Length of hospital stay for inpatients• Persistent bacteriuria aCer completion of antibiotics• Recurrent UTI• Adverse eDects of treatment including minor (e.g. vomiting,
discomfort from IV cannula) and major (e.g. anaphylaxis,
hearing impairment)• Economic costs of treatment (if data available).
Secondary outcomes
Long-term outcome measures.
• Persistent kidney damage (as defined by authors of included
studies)• Hypertension• Chronic kidney disease.
Search methods for identification of studies
Electronic searches
For the 2014 update, we searched the Cochrane Renal Group's
Specialised Register through contact with the Trials' Search Co-
ordinator using search terms relevant to this review. The Cochrane
Renal Group’s Specialised Register contains studies identified from
the following sources.
1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the proceedings of
major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on the
scope of the Cochrane Renal Group. Details of these strategies, as
well as a list of handsearched journals, conference proceedings and
current awareness alerts, are available in the Specialised Register
section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review
update.
For previous search strategies please refer to our earlier reviews
(Bloomfield 2003; Bloomfield 2005; Hodson 2007).
Searching other resources
1. Reference lists of review articles, relevant studies and clinical
practice guidelines.
2. Letters seeking information about unpublished or incomplete
studies to investigators known to be involved in previous
studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and
abstracts of studies relevant to the review. Titles and abstracts
were screened independently by four authors, who discarded
studies that were not applicable. However, studies and reviews
that included relevant data or information on studies were retained
initially. Four authors independently assessed retrieved abstracts,
and if necessary the full text, to determine which studies satisfied
the inclusion criteria.
Antibiotics for acute pyelonephritis in children (Review)
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Data extraction and management
Data extraction was carried out independently by four authors
using standard data extraction forms. Studies reported in non-
English language journals were translated before assessment.
Where more than one publication of one study existed, reports
were grouped together and the publication with the most complete
data was used in the analyses. Where relevant outcomes were only
published in earlier versions those data were used. Any discrepancy
between published versions was highlighted.
Assessment of risk of bias in included studies
The following items were independently assessed by four authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?* Participants and personnel* Outcome assessors• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e4ect
For dichotomous outcomes (persistent bacteriuria, recurrent UTI,
persistent clinical symptoms, presence of kidney parenchymal
damage, adverse eDects) results were expressed as risk ratio
(RR) with 95% confidence intervals (CI). Where continuous
scales of measurement were used to assess the eDects of
treatment (duration of fever, inflammatory markers, extent of
kidney parenchymal damage), the mean diDerence (MD) was used.
Unit of analysis issues
The unit of analysis was the study participant and not events, that
is, the number of children with acute pyelonephritis rather than the
number of episodes of acute pyelonephritis per child.
Dealing with missing data
Where data were missing or unclear, we contacted the original
authors of studies to request additional data. An attempt to obtain
the preliminary results of the terminated study (NCT00724256)
was made by contacting the lead investigator. We did not impute
missing data.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi squared test on N-1 degrees
of freedom with an alpha of 0.1 used for statistical significance
and the I2 statistic (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
We planned to assess publication bias by constructing funnel plots;
however, there were insuDicient data in each meta-analysis to
enable this analysis to be conducted.
Data synthesis
Data were pooled using the random-eDects model but the fixed-
eDect model was also used to ensure robustness of the model
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was planned to explore possible sources of
heterogeneity (participants, treatments and study quality) but
could not be undertaken because of the small number of studies
for each comparison. Heterogeneity among participants could be
related to age (infants versus adolescents) and pre-existing renal
tract pathology. Heterogeneity in treatment could be related to
inpatient versus outpatient management, prior antibiotics used
and the antibiotic, dose, duration and route of administration of
therapy.
Sensitivity analysis
Sensitivity analysis was planned to identify individual studies that
were contributing to significant heterogeneity (I2 value greater than
75%) but the I2 values of all meta-analyses were less than 50% so
sensitivity analysis was not undertaken.
R E S U L T S
Description of studies
Results of the search
First version published 2003
The initial search in September 2002 identified 1520 titles and
abstracts of which 51 were screened. We found that 16 parallel
RCTs (16 reports) involving 1872 children fulfilled the eligibility
criteria and were included in the review. We excluded 11 studies (11
reports) (Bloomfield 2003).
Review updates published 2005 and 2007
A search in June 2004 identified two additional studies (three
reports) (Chong 2003; Montini 2007). A total of 18 studies (19
reports) involving 2612 children were included in our 2005 review
update (Bloomfield 2005).
A search from 2004 to July 2007 identified 26 reports of which
16 were excluded (not randomised, mixed populations or wrong
interventions). We included five new studies (nine reports) (Banfi
1993; Cheng 2006; Fujii 1987; Neuhaus 2008; Noorbakhsh 2004).
The final results of the multicentre study by Montini 2007 were
published and included in this update. We included 23 studies (29
reports) that involved 3407 children in the 2007 update (Hodson
2007).
Review update 2014
A search in 10 April 2014 identified 32 reports. In addition, a
previously excluded study was re-evaluated and included because
it had been excluded incorrectly based on how outcomes were
reported. Khan 1981 had been previously excluded because results
Antibiotics for acute pyelonephritis in children (Review)
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were reported as episodes of acute pyelonephritis rather than
number of patients with an episode of acute pyelonephritis.
We excluded 17 studies (17 reports) and identified one eligible
study that was terminated (see Characteristics of ongoing studies);
contact with the triallists confirmed that no results were available
(NCT00724256). We found that nine new records were further
reports of four previously included studies (Benador 2001; Cheng
2006; Montini 2007; Neuhaus 2008). Reports relating to Benador
2001, Cheng 2006 and Montini 2007 did not provide any new data;
however, the final results of Neuhaus 2008 (two new reports) were
published in September 2008 and results were included in this
review update. Four reports were of three newly identified studies
(Bocquet 2012; Bouissou 2008; Marild 2009). This update included
27 studies (42 reports) that involved 4452 children.
See Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
The characteristics of the 27 included studies are summarised in
Characteristics of included studies.
Participants
Studies recruited participants from the ages of two weeks to 16
years. Three studies did not specify age range (Bakkaloglu 1996;
Levtchenko 2001; Pylkkänen 1981).
Healthcare settings• Children received treatment while inpatients in seven studies
(Bakkaloglu 1996; Carapetis 2001; Chong 2003; Fujii 1987;
Kafetzis 2000; Montini 2007; Vigano 1992).• Children were treated as outpatients only in four studies (Baker
2001; Khan 1981; Pylkkänen 1981; Repetto 1984).• Children received treatment in both in- and outpatient settings
in 16 studies (Banfi 1993; Benador 2001; Bocquet 2012;
Bouissou 2008; Cheng 2006; Fischbach 1989; Francois 1997;
Hoberman 1999; Grimwood 1988; Levtchenko 2001; Marild 2009;
Neuhaus 2008; Noorbakhsh 2004; Schaad 1998; Toporovski
1992; Vilaichone 2001).
Urine collection• All urine specimens were collected by suprapubic aspiration,
catheter or midstream specimens in 14 studies (Banfi 1993;
Baker 2001; Bouissou 2008; Carapetis 2001;Chong 2003;
Grimwood 1988; Hoberman 1999; Kafetzis 2000; Khan 1981;
Neuhaus 2008; Pylkkänen 1981; Repetto 1984; Toporovski 1992;
Vigano 1992).• Specimens were obtained by strap-on bag collection in nine
studies (Benador 2001; Bocquet 2012; Cheng 2006; Levtchenko
2001; Marild 2009; Montini 2007; Noorbakhsh 2004; Schaad 1998;
Vilaichone 2001).• The method of urine collection was not specified in four studies
(Bakkaloglu 1996; Fischbach 1989; Francois 1997; Fujii 1987).
Diagnosis• All participants had acute pyelonephritis in 22 studies (Baker
2001; Bakkaloglu 1996; Benador 2001; Bocquet 2012; Bouissou
2008; Carapetis 2001; Cheng 2006; Chong 2003; Fischbach
1989; Francois 1997; Fujii 1987; Hoberman 1999; Kafetzis 2000;
Levtchenko 2001; Marild 2009; Montini 2007; Neuhaus 2008;
Noorbakhsh 2004; Schaad 1998; Toporovski 1992; Vigano 1992;
Vilaichone 2001).• Five studies enrolled children with both acute pyelonephritis
and lower UTI (Banfi 1993; Grimwood 1988; Khan 1981;
Pylkkänen 1981; Repetto 1984); data from children with acute
pyelonephritis, which could be separated, were included in this
review.
Definition of acute pyelonephritis
All studies required positive urine culture. Additional criteria
required for diagnosis of acute pyelonephritis in children with UTI
varied among studies:
• Four studies required fever > 38°C (Baker 2001; Bocquet 2012;
Hoberman 1999; Khan 1981).• Eight required fever and at least one additional clinical feature
(Bakkaloglu 1996; Carapetis 2001; Chong 2003; Grimwood 1988;
Noorbakhsh 2004; Repetto 1984; Schaad 1998; Toporovski 1992).• Nine required fever, clinical features and/or laboratory
abnormalities (CRP, ESR, white blood count) (Bouissou 2008;
Fischbach 1989; Francois 1997; Kafetzis 2000; Levtchenko 2001;
Marild 2009; Montini 2007; Pylkkänen 1981; Vigano 1992).• Three required fever, clinical features and acute kidney
parenchymal injury on DMSA scan (Benador 2001; Neuhaus
2008; Vilaichone 2001).• Five other studies (Bocquet 2012; Chong 2003; Hoberman 1999;
Levtchenko 2001; Montini 2007) provided information on the
number of children with acute pyelonephritis based on clinical
characteristics, who had DMSA abnormalities at study entry.• One study required fever with computer tomography scan
evidence of acute lobular nephronia (Cheng 2006).
Two studies did not report the definition used for acute
pyelonephritis (Banfi 1993; Fujii 1987).
Commonly reported exclusion criteria• Impaired kidney function (12 studies: Carapetis 2001; Chong
2003; Fischbach 1989; Francois 1997; Kafetzis 2000; Khan 1981;
Noorbakhsh 2004; Repetto 1984; Schaad 1998; Toporovski 1992;
Vigano 1992; Vilaichone 2001).• Known severe urinary tract abnormality (14 studies: Baker 2001;
Benador 2001; Bocquet 2012; Bouissou 2008; Francois 1997;
Hoberman 1999; Khan 1981; Levtchenko 2001; Marild 2009;
Neuhaus 2008; Noorbakhsh 2004; Repetto 1984; Vigano 1992;
Vilaichone 2001).• Known sensitivity to study medications (17 studies: Banfi 1993;
Baker 2001; Benador 2001;Bocquet 2012; Carapetis 2001; Chong
2003; Fischbach 1989; Francois 1997; Hoberman 1999; Kafetzis
2000; Marild 2009; Noorbakhsh 2004; Repetto 1984; Schaad
1998; Toporovski 1992; Vigano 1992; Vilaichone 2001).
Other exclusion criteria• Recent antibiotic use (10 studies: Banfi 1993; Baker 2001;
Bocquet 2012; Chong 2003; Fischbach 1989; Kafetzis 2000;
Marild 2009; Montini 2007; Noorbakhsh 2004; Vilaichone 2001).• Previous UTI (seven studies: Bouissou 2008; Fischbach 1989;
Francois 1997; Hoberman 1999; Marild 2009; Montini 2007;
Vilaichone 2001).
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• Clinical signs of shock at presentation (six studies: Baker 2001;
Bocquet 2012; Francois 1997; Hoberman 1999; Montini 2007;
Neuhaus 2008).• Immune compromise (six studies: Banfi 1993; Bouissou 2008;
Carapetis 2001; Francois 1997; Noorbakhsh 2004; Schaad 1998).• Known hearing impairment (four studies: Carapetis 2001; Chong
2003; Kafetzis 2000; Vigano 1992).• Uncomplicated acute pyelonephritis (APN) (one study: Cheng
2006).
Four studies did not specify any exclusion criteria (Bakkaloglu 1996;
Fujii 1987; Grimwood 1988; Pylkkänen 1981).
Study comparisons
The 27 included studies evaluated eight diDerent comparisons.
• Four studies compared oral therapy with short duration IV
therapy followed by oral therapy (Bocquet 2012; Hoberman
1999; Montini 2007; Neuhaus 2008).• In six studies, short duration IV therapy (three to four days)
followed by oral therapy was compared with long duration
IV therapy (seven to 14 days) (Benador 2001; Bouissou 2008;
Francois 1997; Levtchenko 2001; Noorbakhsh 2004; Vilaichone
2001).• A single dose of parenteral antibiotic added to oral therapy was
compared to oral therapy alone in one study (Baker 2001).• Three studies compared diDerent dosing frequencies of the
same antibiotic agents (Carapetis 2001; Chong 2003; Vigano
1992).• Seven studies compared diDerent antibiotics (Banfi 1993;
Bakkaloglu 1996; Fischbach 1989; Kafetzis 2000; Marild 2009;
Schaad 1998; Toporovski 1992). Toporovski 1992 included two
experimental groups who received diDerent doses of antibiotic.
Because treatment response did not diDer, experimental group
data were combined.• Three studies compared diDerent durations of antibiotics
(Cheng 2006; Khan 1981; Pylkkänen 1981).• Two studies assessed single dose parenteral therapy against
seven to 10 days of oral antibiotic therapy (Grimwood 1988;
Repetto 1984).• One study compared ampicillin suppositories with oral
ampicillin (Fujii 1987).
Reported outcomes
Not all studies reported the same outcomes. Table 1shows the
outcomes reported for each study comparison.
Excluded studies
We excluded a total of 43 studies because: data from children
with acute pyelonephritis could not be separated from those with
lower UTI (18), children had lower UTI only (8), antibiotics were
studied as prophylactic agents (5), the studies involved ineligible
interventions or populations (5) or the study was not randomised
(7).
Risk of bias in included studies
The assessment of risk of bias is shown in Figure 2 and Figure 3.
Figure 2 shows the proportion of studies assessed as low, high or
unclear risk of bias for each risk of bias indicator. Figure 3 shows the
risk of bias indicators for individual studies.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Allocation
Sequence generation was considered to be at low risk of bias in
12 studies (Baker 2001; Benador 2001; Bocquet 2012; Bouissou
2008; Carapetis 2001; Fischbach 1989; Francois 1997; Grimwood
1988; Marild 2009; Montini 2007; Neuhaus 2008; Toporovski 1992)
and assessed at high risk in three studies (Cheng 2006; Khan 1981;
Noorbakhsh 2004). Randomisation methods were not reported in
12 studies.
Allocation concealment was considered to be at low risk of bias in
six studies (Baker 2001; Benador 2001; Bouissou 2008; Marild 2009;
Montini 2007; Neuhaus 2008) and high risk in three studies (Cheng
2006; Khan 1981;Noorbakhsh 2004). Allocation concealment was
assessed as unclear in 18 studies.
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Blinding
Participants and investigators were not blinded in any of the
included studies. The absence of blinding was considered to
be a high risk of bias because symptom reporting and clinical
management could be influenced by knowledge of the treatment
group (performance bias). Bakkaloglu 1996 was reported to be
double-blinded but antibiotics were administered at diDerent
frequencies and no placebos were given.
Outcome assessors (detection bias) were blinded in 17 studies
(Baker 2001; Benador 2001; Bocquet 2012; Bouissou 2008; Chong
2003; Francois 1997; Grimwood 1988; Hoberman 1999; Kafetzis
2000; Khan 1981; Levtchenko 2001; Montini 2007; Neuhaus 2008;
Pylkkänen 1981; Schaad 1998; Vigano 1992; Vilaichone 2001).
Blinding of outcome assessors was not carried out in nine
studies (Bakkaloglu 1996; Banfi 1993; Carapetis 2001; Cheng 2006;
Fischbach 1989; Marild 2009; Noorbakhsh 2004; Repetto 1984;
Toporovski 1992). There was no reporting of outcome assessment
blinding in Fujii 1987 (abstract only available).
Incomplete outcome data
Not all studies reported all outcomes. The reported outcomes from
each of the included studies are summarised in Table 1. Incomplete
outcome data was considered to be at low risk of bias in 19 studies
because they reported outcomes in more than 90% of participants
(Baker 2001; Bakkaloglu 1996; Benador 2001; Carapetis 2001;
Cheng 2006; Chong 2003; Fischbach 1989; Francois 1997; Fujii
1987; Grimwood 1988; Kafetzis 2000; Levtchenko 2001; Marild
2009; Noorbakhsh 2004; Repetto 1984; Schaad 1998; Toporovski
1992; Vigano 1992; Vilaichone 2001). Attrition and exclusion of
participants aCer the randomisation process was considered to
be at a high risk of bias in seven studies (Banfi 1993; Bocquet
2012; Bouissou 2008; Hoberman 1999; Montini 2007; Neuhaus 2008;
Pylkkänen 1981) and unclear in Khan 1981.
Selective reporting
There were 13 studies that reported bacteriological, clinical and
adverse outcomes and were considered at low risk of bias (Baker
2001; Bakkaloglu 1996; Banfi 1993; Benador 2001; Carapetis 2001;
Chong 2003; Fischbach 1989; Francois 1997; Kafetzis 2000; Marild
2009; Montini 2007; Schaad 1998; Toporovski 1992). Fujii 1987 was
an abstract and did not clearly indicate outcomes investigated. The
remaining 13 studies did not report all three types of outcomes and
were considered at high risk of bias.
Other potential sources of bias
We assessed that 11 studies were at high risk of bias because
they reported receiving funding from pharmaceutical companies
(Baker 2001; Banfi 1993; Bouissou 2008; Hoberman 1999; Kafetzis
2000; Marild 2009; Neuhaus 2008; Noorbakhsh 2004; Pylkkänen
1981; Schaad 1998; Toporovski 1992). Four received funding from
hospital grants (Bocquet 2012; Chong 2003; Grimwood 1988) or a
government grant (Montini 2007) and were considered at low risk of
bias. The source of funding in the remaining 12 studies was unclear.
E4ects of interventions
See: Summary of findings for the main comparison Oral versus
IV followed by oral (11 days) therapy for acute pyelonephritis in
children; Summary of findings 2 Short duration (3 to 4 days) versus
long duration (7 to 14 days) IV therapy for acute pyelonephritis
in children; Summary of findings 3 DiDerent dosing regimens of
aminoglycosides (daily versus 8 hourly) for acute pyelonephritis
in children; Summary of findings 4 Agent: Third generation
cephalosporin versus other antibiotic for acute pyelonephritis in
children
Because results from random and fixed-eDect models did not
diDer, only results from the random-eDects model were reported.
Few studies were available for pooling in meta-analyses. No pre-
planned subgroup analyses for outcomes according to patient age
(infant, child, adolescent) were possible from the available data.
Post hoc subgroup analyses were reported for age (less than or
greater than one year of age, Benador 2001) and VUR (Benador
2001; Hoberman 1999; Vilaichone 2001) and delay in treatment
(less than or greater than seven days, Levtchenko 2001).
Oral therapy versus sequential IV therapy and oral therapy
We found four studies (Bocquet 2012; Hoberman 1999; Montini
2007; Neuhaus 2008) involving 1131 children compared oral
antibiotics (cefixime, ceCibuten or amoxicillin/clavulanic acid) for
10 to 14 days with IV cefotaxime (Hoberman 1999) or ceCriaxone
(Bocquet 2012; Montini 2007; Neuhaus 2008) for three to four days
or until resolution of fever followed by oral antibiotics to complete
the course of therapy.
• Time to resolution of fever did not diDer significantly between
groups (Analysis 1.1 (2 studies, 808 children): MD 2.05 hours, 95%
CI -0.84 to 4.94; I2 = 0%). Neuhaus 2008 reported the number
of children with fever on day three did not diDer significantly
between groups (Analysis 1.2 (1 study, 152 children): RR 0.79,
95% CI 0.30 to 2.06).• The number of children with persistent UTI at 72 hours aCer
commencing therapy did not diDer significantly between groups
(Analysis 1.3 (2 studies, 542 children): RR 1.10, 95% CI 0.07 to
17.41).• Montini 2007 reported no significant diDerence between groups
in the mean levels of inflammatory markers: WCC (Analysis 1.4.1
(1 study, 473 children): MD 0.30 x 109/L, 95% CI -0.30 to 0.90), ESR
(Analysis 1.4.2 (1 study, 338 children): MD -1.80 mm/60 min, 95%
CI-8.20 to 4.60]) or CRP (Analysis 1.4 (1 study, 486 children): MD
1.10 mg/L, 95% CI -2.18 to 4.38).• Hoberman 1999 reported no significant diDerence between
groups in the rate of recurrences of bacteriuria (Analysis 1.5.1 (1
study, 287 children): RR 0.65, 95% CI 0.28 to 1.51) or symptomatic
UTI within six months (Analysis 1.5.2 (1 study, 287 children): RR
0.67, 95% CI 0.27 to 1.67).• There were no significant diDerences among treatment groups
in the rate of persistent kidney parenchymal defects on DMSA
scan whether considered in relation to the total number of
children with acute pyelonephritis (Analysis 1.6.1 (4 studies, 943
children): RR 0.82, 95% CI 0.59 to 1.12; I2 = 41%) or only those
with defects on the initial DMSA scan (Analysis 1.6.2 (4 studies,
681 children): RR 0.79, 95% CI 0.31 to 1.03; I2 = 19%). Hoberman
1999 reported no significant diDerence between groups in the
size of persistent kidney parenchymal defects on DMSA scan
(Analysis 1.7 (1 study, 272 children): MD -0.70, 95% CI -1.74 to
0.34).• Post hoc subgroup analysis (Analysis 1.8) by Hoberman 1999
found no diDerence in the number of kidney parenchymal
defects on DMSA scan at six months between children with
VUR (Analysis 1.8.1 (1 study, 107 children): RR 1.88, 95% CI
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0.83 to 4.24) and those without VUR (Analysis 1.8.2 (1 study,
107 children): RR 0.80, 95% CI 0.23 to 2.73). However, post
hoc analysis (Analysis 1.8.4) raised the possibility that among
children with VUR (grades III-V), persistent kidney parenchymal
defects on DMSA scan at six months occurred more frequently
aCer oral than IV therapy (RR 7.33, 95% CI 1.00 to 54.01).• The average cost of treatment for each patient was USD 3630 and
USD 7382 for oral and IV groups respectively (Hoberman 1999).• Adverse eDects were reported in three studies (Bocquet 2012;
Montini 2007; Neuhaus 2008). No children experienced therapy-
related adverse eDects in Neuhaus 2008. In Bocquet 2012
two children experienced vomiting with oral cefixime and
required change to parenteral therapy. In Montini 2007 15
children experienced diarrhoea or vomiting (13), erythema (1)
and leucopenia (1) with oral amoxicillin and clavulanic acid;
10 required a change of antibiotics. In the same study three
children experienced diarrhoea (1), erythema (1) and candida (1)
with ceCriaxone; none required change of treatment. Hoberman
1999 did not report on adverse eDects.
Sequential short duration (three to four days) IV therapy and
oral therapy versus long duration (seven to 14 days) IV therapy
There were six studies (Benador 2001; Bouissou 2008; Francois
1997; Levtchenko 2001; Noorbakhsh 2004; Vilaichone 2001)
involving 917 children that compared oral therapy aCer an initial
three to four days of IV therapy with a long duration of IV therapy
alone. Two studies compared IV ceCriaxone (three to four days)
followed by oral cefixime (Benador 2001) or ceCibuten (Vilaichone
2001) with IV ceCriaxone (10 days). Levtchenko 2001 compared IV
temocillin (three days) followed by oral amoxicillin or amoxicillin/
clavulanic acid with IV temocillin (seven days). Noorbakhsh 2004
compared IV ceCriaxone (two to three days) followed by oral
ceCibuten with IV amikacin or gentamicin with IV ampicillin (14
days). Francois 1997 compared IV cefotaxime (four days) followed
by oral amoxicillin/clavulanic acid with IV cefotaxime (14 days).
Bouissou 2008 compared IV netilmicin (two days) and ceCriaxone
(three days) followed by oral antibiotics (cefixime, amoxicillin/
clavulanic acid, TMP/SMX) chosen according to sensitivity with IV
netilmicin (two days) and ceCriaxone (eight days). Benador 2001
and Levtchenko 2001 also converted the IV group to oral therapy
aCer seven to 10 days to complete 15 to 21 days of treatment.
• There was no significant diDerence between the risk of
persistent bacteriuria at the end of treatment (Analysis 2.1 (4
studies, 305 children): RR 0.78, 95% CI 0.24 to 2.55; I2 = 0%).• There was no significant diDerence between groups for
recurrent UTI within six months (Analysis 2.2 (5 studies, 993
children): RR 0.97, 95% CI 0.58 to 1.62; I2 = 0%).• The number of persisting kidney parenchymal defects seen on
DMSA scan at three to six months did not diDer significantly
between treatment groups when considered in relation to the
total number of children with acute pyelonephritis (Analysis
2.3.1 (4 studies, 726 children): RR 1.01, 95% CI 0.80 to 1.29; I2 =
0%) or only those with defects on the initial DMSA scan (Analysis
2.3.2 (3 studies, 315 children): RR 1.10, 95% CI 0.84 to 1.45; I2 =
0%).• Post hoc subgroup analysis showed that the number of children
with persisting kidney parenchymal defects on DMSA scan did
not diDer between those with VUR (Analysis 2.4.1 (2 studies, 81
children): RR 0.99, 95% CI 0.69 to 1.43; I2 = 0%) and without VUR
(Analysis 2.4.2 (2 studies, 173 children): RR 1.19, 95% CI 0.81 to
1.76; I2 = 0%), those aged under one year (Analysis 2.4.3 (1 study,
22 children): RR 1.46, 95% CI 0.71 to 3.01) and aged one year and
over (Analysis 2.4.4 (1 study, 54 children): RR 0.89, 95% CI 0.59
to 1.34), and those who had a delay of treatment of less than
seven days (Analysis 2.4.5 (1 study, 13 children): RR 1.52, 95% CI
0.59 to 3.92) or more than seven days (Analysis 2.4.6 (1 study, 8
children): RR 2.10, 95% CI 0.92 to 4.77).• Adverse eDects were reported in Francois 1997 and Vilaichone
2001; both related to gastrointestinal upsets, and frequency did
not diDer between therapy routes (Analysis 2.5.1 (2 studies, 175
children): RR 1.29, 95% CI 0.55 to 3.05; I2 = 0%). Four studies
did not report on adverse eDects (Benador 2001; Bouissou 2008;
Levtchenko 2001; Noorbakhsh 2004).• Duration of hospitalisation was 4.9 days for the IV and oral group
compared with 9.8 days for the IV group (Vilaichone 2001).• Costs of treatment for four days of IV therapy followed by six
days of oral therapy were 513 French Francs (range 176 to 896)
compared with 3545 French Francs (range 2478 to 4673) for 10
days of IV therapy (Francois 1997).
Single dose parenteral therapy and oral treatment versus oral
therapy alone
Baker 2001 (69 children) compared the addition of a single
intramuscular dose of the third generation cephalosporin,
ceCriaxone, to an oral course of TMP/SMX. There was no significant
diDerence in:
• persistence of bacteriuria aCer 48 hours (Analysis 3.1: RR 0.77,
95% CI 0.19 to 3.20)• persistence of clinical symptoms (Analysis 3.2: RR 0.82, 95% CI
0.24 to 2.81), or• total adverse events (Analysis 3.4.1: RR 1.37, 95% CI 0.33 to 5.68)
between groups.
No child developed symptomatic UTI during one month aCer
treatment.
Di4erent dosing regimens of aminoglycoside therapy
Three studies that involved 495 children compared daily parenteral
administration of gentamicin (Carapetis 2001; Chong 2003)
or netilmicin (Vigano 1992) to eight-hourly administration of
aminoglycosides.
• There was no significant diDerence in the risk for persisting
bacteriuria one to three days aCer commencing treatment with
either dose frequency (Analysis 4.1 (3 studies, 435 children): RR
1.05, 95% CI 0.15 to 7.27).• Carapetis 2001 reported no diDerence in numbers of children
with persisting clinical symptoms aCer three days of gentamicin
(Analysis 4.2 (1 study, 179 children): RR 1.98, 95% CI 0.37 to
10.53).• Vigano 1992 reported persisting bacteriuria one week aCer
(Analysis 4.3 (1 study, 144 children): RR 2.84, 95% CI 0.12 to
68.57) and recurrent UTI within one month (Analysis 4.4 (1 study,
144 children): RR 1.18, 95% CI 0.33 to 4.23) aCer completing
netilmicin treatment did not diDer between treatment groups.• There was no significant diDerence in numbers of children with
hearing impairment (Analysis 4.5 (3 studies, 271 children): RR
2.83, 95% CI 0.33 to 24.56; I2 = 0%) or kidney dysfunction
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(Analysis 4.6 (3 studies, 419 children): RR 0.75, 95% CI 0.20 to
2.82; I2 = 0%).• Chong 2003 reported mean time to resolution of fever with
gentamicin did not diDer between groups (Analysis 4.7 (1 study,
172 children): MD 2.40 hours, 95% CI -7.90 to 12.70). Median time
to resolution of fever was 27 hours (interquartile range 15 to 48
hours) with daily dosing and 33 hours (interquartile range 12 to
48 hours) with eight-hourly dosing in a second study (Carapetis
2001).
Di4erent antibiotic agents
Six studies compared diDerent antibiotics (Bakkaloglu 1996;
Carapetis 2001; Chong 2003; Kafetzis 2000; Schaad 1998; Vigano
1992).
Third generation cephalosporins versus other antibiotics
In four studies involving 491 children treatment with third
generation cephalosporins (IV cefotaxime (Fischbach 1989), oral
cefetamet (Toporovski 1992) or oral ceCibuten (Banfi 1993; Marild
2009) were compared with amoxicillin/clavulanic acid (Fischbach
1989; Toporovski 1992) or TMP/SMX (Banfi 1993; Marild 2009).
• There was no significant diDerence in the number of children
with persistent bacteriuria aCer 48 hours of therapy (Analysis 5.1
(3 studies, 433 children): RR 2.41, 95% CI 0.98 to 5.93; I2 = 0%).• There was no significant diDerence in numbers of children who
had recurrent UTI at 4 to 10 days aCer treatment (Analysis 5.2 (4
studies, 419 children): RR 1.23, 95% CI 0.32 to 4.74; I2 = 0%).• A significantly greater number of children treated with TMP/
SMX had persistent clinical symptoms at four to 10 days aCer
treatment compared with those treated with a third generation
cephalosporin (Analysis 5.3 (3 studies, 471 children): RR 0.28,
95% CI 0.13 to 0.62; I2 = 0%). The study by Marild 2009
contributed to 94% of the weight of this result.• Fischbach 1989 reported no significant diDerence in numbers of
children with persistent fever for more than 48 hours (Analysis
5.4 (1 study, 20 children): RR 5.00, 95% CI 0.27 to 92.62).• Banfi 1993 reported no significant diDerence between groups in
the rate of recurrences of bacteriuria (Analysis 5.5 (1 study, 28
children): RR 2.14, 95% CI 0.11 to 40.30) or symptomatic UTI at
four to six weeks (Analysis 5.6; no symptomatic UTIs in either
group).• All four studies reported adverse eDects. There was no
significant diDerence in numbers of children who experienced
gastrointestinal adverse eDects (Analysis 5.7 (4 studies, 591
children): RR 0.93, 95% CI 0.34 to 2.58; I2 = 0%). Marild
2009 reported that four children in each group discontinued
treatment because of adverse reactions (Analysis 5.8 (1 study,
461 children): RR 0.49, 95% CI 0.12 to 1.94).
Third generation cephalosporins versus fourth generation
cephalosporins (Analysis 6)
In Schaad 1998, which included 299 children, IV cefepime (a fourth
generation cephalosporin) was compared to IV ceCazidime (a third
generation cephalosporin).
• No significant diDerences between groups were detected in
numbers of children with persistent or recurrent bacteriuria
with the same pathogen at diDerent time points aCer therapy
(Analysis 6.1).
• Recurrent UTI with a diDerent pathogenic organism at four to six
weeks did not diDer between groups (Analysis 6.2: RR 1.19, 95%
CI 0.45 to 3.18).• There were no significant diDerences in the occurrence of an
unsatisfactory clinical response at diDerent time points aCer
therapy (Analysis 6.3).• The frequency of adverse eDects did not diDer between
treatment groups (Analysis 6.4).
Ce0riaxone versus cefotaxime
Bakkaloglu 1996 compared ceCriaxone and cefotaxime in 100
children aged over 24 months.
• No child had persistent bacteriuria at 48 hours (Analysis 7.1).• There were no significant diDerences between groups for
bacteriuria at the end of treatment (Analysis 7.2.1: RR 0.87,
95% CI 0.37 to 2.03), for recurrent infection at one month aCer
therapy (Analysis 7.3.1: RR 0.68, 95% CI 0.30 to 1.50), or for total
adverse events (Analysis 7.4.1: RR 0.67, 95% CI 0.12 to 3.82).• Post hoc subgroup analysis (Analysis 7.2.2 and Analysis 7.2.3)
revealed no diDerences in outcomes for bacteriuria at the end of
treatment or recurrent UTI at one month aCer therapy between
children with and without abnormalities on imaging studies of
the urinary tract.
Aminoglycosides
Kafetzis 2000 compared the aminoglycosides isepamicin and
amikacin in 16 children.
• No child in either group had persistent bacteriuria aCer 48 hours
of treatment, or seven days or 30 days aCer treatment (Analysis
8.1).• Mean time to resolution of fever in each group was identical (24
hours).• No child in either treatment group developed hearing
impairment on testing.
Duration of antibiotic administration
Four studies compared diDerent durations of antibiotic
administration (Cheng 2006; Grimwood 1988; Pylkkänen 1981;
Repetto 1984).
Ten days versus 42 days of oral sulphafurazole
The study by Pylkkänen 1981 involved 149 children and compared
10 days with 42 days of oral sulphafurazole.
• Recurrence of UTI within one month of ceasing therapy was
significantly higher in children treated for 10 days compared
with children treated for 42 days (Analysis 9.1: RR 17.70, 95% CI
2.42 to 129.61).• The number of children with recurrent UTI from one to 12
months aCer ceasing therapy did not diDer between groups
(Analysis 9.2: RR 0.87, 95% CI 0.40 to 1.88).
Single dose parenteral antibiotic therapy versus seven to 10
days of oral therapy
Grimwood 1988 and Repetto 1984 (involving a total of 61 children)
compared single dose parenteral antibiotic therapy with seven to
10 days of oral therapy.
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• There were no significant diDerences in the number of children
with persistent bacteriuria aCer treatment (Analysis 10.1 (2
studies, 35 children): RR 1.73, 95% CI 0.18 to 16.30; I2 = 15%) or
with recurrent UTI within six weeks (Analysis 10.2 (2 studies, 35
children): RR 0.24, 95% CI 0.03 to 1.97).
Three weeks with two weeks of antibiotics
Cheng 2006, which involved 80 children, compared three weeks
with two weeks of antibiotics for children with acute lobar
nephronia. Antibiotics were chosen according to sensitivities.
• Seven children treated for two weeks had persistent or recurrent
bacteriuria; this was not significantly diDerent (Analysis 11.1: RR
0.07, 95% CI 0.00 to 1.19).• Two children had recurrence of clinical symptoms with
bacteriuria; this was not significantly diDerent (Analysis 11.2: RR
0.21, 95% CI 0.01 to 4.24).
Three days with 10 days of antibiotics
Khan 1981 (54 children) compared three and 10 days of oral
antibiotics. Data were reported as episodes of UTI (asymptomatic,
lower tract, APN) and could not be included in a meta-analysis. Of
31 episodes of UTI, 23 were cured in 27 children in the three day
treatment group and 25 of 31 episodes were cured in 27 children
in the 10 day treatment group. Of episodes of acute pyelonephritis,
four were cured in five episodes in the three day treatment group
and five were cured in six episodes in the 10 day treatment group.
Di4erent routes of antibiotic administration
Fujii 1987, which reported on 105 children, compared ampicillin
administered by suppository with oral administration.
• There was no significant diDerence between treatments in the
risk of persistent clinical symptoms (Analysis 12.1: RR 0.89, 95%
CI 0.51 to 1.56) or bacteriuria (Analysis 12.2: RR 0.89, 95% CI 0.53
to 1.50).
D I S C U S S I O N
Summary of main results
This review was designed to include all RCTs addressing all aspects
of antibiotic treatment for children with acute pyelonephritis.
Identified studies formed a heterogeneous group with few studies
addressing the same or similar comparisons to enable assessment
in meta-analyses. The 27 included studies addressed a variety of
diDerent questions related to the therapy of children with acute
pyelonephritis.
Oral therapy versus IV therapy
Four studies compared an oral antibiotic (ceCibuten, cefixime or
amoxicillin/clavulanic acid) alone with IV therapy (cefotaxime or
ceCriaxone) followed by oral therapy. These studies found:
• No significant diDerence in bacteriological outcomes between
groups.• The number of children with kidney parenchymal damage on
DMSA scan at follow-up whether expressed as a proportion of
the total number considered to have acute pyelonephritis or as
a proportion of those with DMSA changes at entry did not diDer
significantly between groups.
Thus, there were no significant diDerences in eDicacy between
treatment with oral ceCibuten, cefixime and amoxicillin/clavulanic
acid and IV therapy followed by oral therapy. Studies that support
these findings enrolled children older than one month of age and
hence the finding cannot be extrapolated to children aged less than
one month.
Short duration versus long duration IV therapy
A meta-analysis of six studies showed:
• No significant diDerences in clinical or bacteriological outcomes
between IV antibiotic therapy given for three to four days
followed by oral therapy and IV therapy for seven to 14 days.• That the prevalence of kidney parenchymal injury on DMSA
scan at three to six months aCer UTI therapy did not diDer
significantly between treatment groups.
These data show that short duration IV therapy (three to four
days) can be used instead of longer courses of IV therapy to
treat childhood acute pyelonephritis. The findings cannot be
extrapolated to children less than one month of age as such
children were excluded from the studies.
Single daily dosing with aminoglycosides
If IV therapy is required, three studies provide data to support
the safety and eDicacy of daily dosing with aminoglycosides
(gentamicin and netilmicin) compared with eight-hourly dosing
in children with acute pyelonephritis. Once daily dosing has
been studied extensively in adults and is preferred due to
improved eDicacy, similar or reduced toxicity, convenience
and lower costs. These findings have also been supported
in children justifying the use of single daily dosing of
aminoglycosides (Contopoulos-Ioannidis 2004; Jenh 2011),
although aminoglycoside pharmacokinetics and toxicity diDer in
children from adults.
E4icacy of di4erent antibiotics
The seven studies that compared diDerent antibiotics did not
demonstrate any advantage of one agent over another. Four studies
compared a cephalosporin with amoxicillin/clavulanic acid or TMP/
SMX. A meta-analysis of three studies demonstrated that children
treated with oral ceCibuten had a higher clinical cure rate than TMP/
SMX. However one large study (Marild 2009) contributed most of
the weight of the analysis. The study defined clinical cure as the
resolution of all symptoms related to the infection within 10 days.
It is possible that there was some cross-over of symptoms related
to the infection and those due to adverse eDects of medication
such as vomiting. Furthermore, the study did not demonstrate any
diDerence in bacteriological elimination rates despite 15% of the
pathogens responsible for the infection being resistant to TMP/SMX
compared to 2% that were resistant to ceCibuten.
One study demonstrated that a single dose of parenteral
medication added to oral therapy did not improve eDicacy
compared with oral therapy alone.
Adverse events
Adverse events resulting from antibiotics were reported in 16
studies. Events were uncommon and rarely resulted in treatment
discontinuation or significant alteration.
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Overall completeness and applicability of evidence
In this review a comprehensive and extensive literature review
was performed to identify studies that assessed the benefits and
harms of antibiotics to treat children with acute pyelonephritis.
We found that oral antibiotic therapy alone is as eDective as IV
therapy followed by oral therapy, and similarly short IV therapy
is as eDective as longer courses of IV therapy to treat childhood
acute pyelonephritis. It is unknown whether these findings apply to
children less than one month of age since children aged below one
month of age were excluded from studies. The exclusion criteria
for participation in the included studies mean that our findings
may not be generalizable to all children with acute pyelonephritis.
There were 10 studies that excluded children who were severely
ill or clinically unstable. Four studies did not specify any exclusion
criteria. The applicability of the findings in children with uropathy
may also be limited since 10 studies excluded children with known
uropathy. Hoberman 1999 performed a post hoc subgroup analysis
to analyse diDerences in eDicacy between children with or without
VUR but the study was not designed and had no power to detect
diDerences between small subgroups. Further data are required to
determine whether treatment eDicacy diDers in children with non-
dilating VUR (grades I-II) and dilating VUR (grades III-V).
Most of the studies examined the bacteriological eDicacy of
antibiotic therapy. Few studies compared the eDicacy of antibiotic
therapies on the resolution of clinical symptoms other than fever.
None of the 27 included studies analysed the optimal duration of
antibiotic therapy for childhood acute pyelonephritis. Our review
evaluated oral antibiotic regimens in which oral antibiotics were
used either alone or following IV antibiotics for a total duration of
eight to 42 days of therapy. Inadequate data are available on the
benefits and harms of shorter duration therapies (e.g. seven days
or less). Three studies compared single dose parenteral antibiotic
therapy or short course oral therapy with seven to 10 days of oral
therapy and showed no significant diDerences but the studies were
small. This is unlike the evidence supporting the use of short-
course therapies for the treatment of lower urinary tract infections
in children (Michael 2002; Michael 2003).
From the low reported incidence of adverse events, we were only
able to detect common adverse eDects e.g. gastrointestinal upsets.
Generally, RCTs are not powered to detect rare but serious side
eDects e.g. Stevens–Johnson syndrome, so our findings of adverse
eDects may not be generalizable to larger groups of children.
Most of the included studies reported on short-term outcomes.
Nine studies analysed kidney parenchymal damage on DSMA scan
at three to 12 months following an episode of acute pyelonephritis.
Five of the nine studies had a high loss to follow up because of
refusal to do a DMSA scan among well children and one study
(not included) was terminated without any results for this reason
(NCT00724256). The loss to follow up of well children may lead to an
underestimate of the eDect of treatment. As the longest follow up
of children was 12 months, this review cannot provide data on the
likelihood of long term kidney scarring following antibiotic therapy.
Although several studies potentially included adolescents aged to
16 years, none of the studies reported results for diDerent age
groups. Thus we could not determine whether there was any
diDerence in results according to the patients' ages.
Quality of the evidence
The quality of the included studies was quite variable. The main
limitations in the quality of the studies were concealment of
allocation, blinding of participants and personnel and sponsorship
from pharmaceutical companies. Of the 27 included studies, 12
reported adequate sequence generation and six demonstrated
adequate allocation concealment. The lack of adequate sequence
generation and allocation concealment can lead to biased
estimates of treatment eDects in the original study and therefore
the results of a systematic review (Hollis 1999; Juni 1999; Moher
1998; Schulz 1995). All of the studies were unblinded to participants
and personnel primarily because antibiotics were delivered by
the parenteral route compared with oral or used diDerent dosing
regimens. This was considered a high risk of bias because clinicians’
management could be influenced by knowledge of the treatment
group. For blinding of outcome assessors, blinding was adequate
in 17 studies where the primary outcome was bacteriological
or radiological and considered unlikely to be influenced by lack
of blinding. We found that 19 studies provided complete data
reporting and 13 reported on all reasonably expected outcomes
(bacteriological eradication, clinical cure and adverse eDects).
The authors of 11 studies reported receiving sponsorship from
pharmaceutical companies.
The quality of the evidence was assessed according to the GRADE
approach and is displayed in summary of findings tables.
The evidence that oral therapy alone is as eDective as IV therapy
followed by oral therapy in children with acute pyelonephritis is
considered to be of moderate quality. The quality of evidence
was downgraded because of imprecision regarding the time to
resolution of fever and the loss to follow-up for DMSA scans
(Summary of findings for the main comparison).
The evidence that short duration IV therapy followed by oral
therapy is as eDective as long duration IV therapy is considered to
be of moderate quality. The quality of evidence was downgraded
because of unclear or inadequate allocation concealment in the
included studies which may increase the risk of selection bias, the
studies being too small and the loss to follow-up for DMSA scans
(Summary of findings 2).
The evidence that daily dosing of aminoglycosides is as safe and
eDective as thrice daily dosing of aminoglycosides is considered to
be of low quality. The quality of evidence was downgraded because
of unclear allocation concealment in two of three studies and the
small number of participants combined with the low frequency of
events that made the analysis significantly underpowered to detect
a diDerence (Summary of findings 3).
The evidence that third generation cephalosporins are no more
eDective than other antibiotics (amoxicillin/clavulanic acid and
TMP/SMX) is low. The quality of evidence was downgraded
because of unclear allocation, imprecision from sparse data, and
inconsistent bacteriologic results from one study that provided
most of the weight of the meta-analysis (Summary of findings 4).
Potential biases in the review process
We attempted to reduce publication bias by searching multiple
databases and the grey literature without language restriction.
Although the Cochrane Renal Group's Specialised Register contains
the handsearched reports of studies, it is possible that we
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missed unpublished data presented at smaller conferences or
studies published in foreign language journals and low impact
journals. Studies may have been added since our last search of
the register. No data were available from the terminated study
(NCT00724256) aCer personal communication with the lead author.
Not all included studies reported all outcomes. Some outcomes
that would be expected to be known (e.g. resolution of clinical
symptoms) were not reported which may have aDected the results
of meta-analyses.
Agreements and disagreements with other studies or
reviews
A systematic review published in 2008 evaluated an early switch to
oral antibiotics aCer at least one day of initial IV antibiotics with IV
therapy alone for hospitalised patients with acute pyelonephritis
(Vouloumanou 2008). The meta-analysis included both children
and adults with acute pyelonephritis but the data from the two
populations could be separated. It identified all six RCTs in children
that we included in our review for this comparison. The authors
found there was no diDerence in the incidence of kidney scars,
microbiological eradication, clinical cure, reinfection, persistence
of acute pyelonephritis, or adverse events between the two
treatment regimens. This is consistent with our finding that short
duration IV therapy followed by oral therapy is as eDective as longer
courses of IV therapy for the treatment of acute pyelonephritis in
children.
No other systematic reviews were found for the 11 other
comparisons in our review.
This review agrees with recently published guidelines (AAP 2011;
Ammenti 2012; NICE 2007) for the treatment of childhood UTI,
which recommend oral antibiotics for the initial treatment of
children with acute pyelonephritis unless the child is seriously
ill and/or unable to tolerate oral antibiotics. Our findings can be
applied to children aged over one month. The NICE 2007 guidelines
apply to children aged three months or older, the AAP 2011
guidelines apply to children aged 2 to 24 months and the Ammenti
2012 recommendations apply to children aged two months to three
years. The guidelines also suggest seven or more days of antibiotic
treatment but recognise that this is not based on best evidence
because there are no data on the optimal duration of antibiotic
therapy, particularly shorter courses.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The following implications for practice in the treatment of children
with acute pyelonephritis have been identified:
• Oral antibiotics (cefixime, ceCibuten or amoxicillin/clavulanic
acid) given alone for 10 to 14 days are as eDective as sequential IV
therapy given for three days followed by oral therapy for a total
duration of 10 to 14 days suggesting that children with acute
pyelonephritis can be treated eDectively with oral antibiotics.• If IV antibiotic therapy is given, a short course of IV therapy given
for two to four days followed by oral therapy with total therapy
duration of 10 to 21 days is as eDective as a longer duration of IV
antibiotic therapy given for seven to 10 days with total duration
of therapy of 10 to 21 days.• Studies comparing oral therapy alone with IV then oral
antibiotics or IV then oral with IV therapy involved children
greater than one month of age and were biased towards children
who were less sick and so findings cannot be extrapolated to
children less than one month of age or who are severely ill. The
studies were also not stratified according to the grade of VUR
so it remains unclear whether results diDer according to the
presence or absence of dilating VUR (grades III-V).• Adequate data from RCTs are not available to determine the
optimal total duration of antibiotic therapy required for acute
pyelonephritis.
Implications for research
Further RCTs are required to determine the benefits and harms in
children of diDerent ages with acute pyelonephritis of:
• Treatment for shorter periods (seven days or less) compared
with 10 to 14 days.• Initial treatment with oral antibiotics compared with parenteral
therapy or IV then oral therapy compared with IV therapy
in children with dilating VUR or other major urinary tract
malformation.• Treatment with aminoglycosides alone or in combination with
other antibiotics compared with other antibiotics including third
generation cephalosporins in initial parenteral treatment.• Treatment with cheaper and more widely available oral
antibiotics e.g. cephalexin.
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Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration: 1 September 1996 to 31 March 1998• Duration of follow-up: 1 month
Participants • Country: USA• Setting: tertiary hospital ED
Baker 2001 
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• Children 6 months to 12 years; temperature > 38°C and diagnosed as having a UTI based on presenting
history, physical examination and urinalysis findings• Urine collection: MSU or catheter• Number: treatment group 1 (34); treatment group 2 (35)• Mean age (years): treatment group 1 (3.6); treatment group 2 (3.8)• Sex (M/F): treatment group 1 (5/30); treatment group 2 (2/34)• Exclusion criteria: patients with known uropathy; current antibiotic therapy; allergy to study antibi-
otics; clinically unstable patients
Interventions Treatment group 1
• IM ceftriaxone: 50 mg/kg, single dose• Oral TMP/SMX: 5 mg/kg/d twice daily for 10 days
Treatment group 2
• Oral TMP/SMX: 5 mg/kg/d twice daily for 10 days
Outcomes • Urine culture at 48 hours• Admission at 48 hours• UTI and/or admission at 1 month• Adverse effects
Notes • Definition of APN: UTI and fever > 38°C• 87 enrolled; 18 excluded (no growth on urine 14, no FU 4); 69 included
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The patient's nurse blindly selected opaque envelopes containing group as-
signment from a bin"
Allocation concealment
(selection bias)
Low risk "The patient's nurse blindly selected opaque envelopes containing group as-
signment from a bin"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo injections so participants aware of assignment. "Physicians caring
for the patients were unaware of study group assignment".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Clinicians caring for the children were unaware of the assignment at follow up.
"Physician caring for patient at follow-up usually was not the physician who
cared for the patient at first visit". All children had bandage on thigh (IM injec-
tion)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Four (5.5%) lost to FU and excluded. Unlikely to influence results as balanced
across groups.
Selective reporting (re-
porting bias)
Low risk Reported all expected outcomes
Other bias High risk Study grant from Roche Pharmaceuticals, Denver, Colorado
Baker 2001  (Continued)
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Methods • Study design: RCT• Study duration: NS• Duration of follow-up: 1 month
Participants • Country: Turkey• Setting: tertiary IP• Children ≥ 2 years• Urine collection: NS• Number: treatment group 1 (50); treatment group 2 (50)• Mean age ± SD (years): treatment group 1 (8.1 ± 3.6); treatment group 2 (8.3 ± 2.9)• Sex (M/F): treatment group 1 (12/38); treatment group 2 (10/40)• Uropathy: treatment group 1 (24); treatment group 2 (21)• Exclusion criteria: NS
Interventions Treatment group 1
• IV ceftriaxone: 50 mg/kg daily for 10 days
Treatment group 2
• IV cefotaxime: 50 mg/kg twice daily for 10 days
Outcomes • Persistent bacteriuria at 2 to 3 days• Persistent bacteriuria at 10 days• Recurrent UTI within 4 to 5 weeks• Adverse events
Notes • Definition of APN: UTI and 2+ of fever, flank pain, pyuria, bacteriuria.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Said to be "double-blind, randomized clinical trial" but no placebo injection
given to ceftriaxone group
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Lack of blinding could influence assessment of clinical response
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients included in follow-up
Selective reporting (re-
porting bias)
Low risk Reports expected outcomes (clinical and bacteriological response, adverse ef-
fects)
Other bias High risk Grant from Hoffmann La Roche Ltd
Bakkaloglu 1996 
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Methods • Study design: parallel RCT• Study duration: 31 August 1989 to 16 November 1990• Duration of follow-up: 4 to 6 weeks
Participants • Country: South America/Europe• Setting: multicentre; IP/OP• Symptomatic UTI including children with uncomplicated, complicated and upper UTI; aged: ≥ 12 years• Urine collection: clean catch, catheter, suprapubic• Number* Safety population/APN: treatment group 1 (154/52); treatment group 2 (74/21)* Efficacy population/APN: treatment group 1 (101/36); treatment group 2 (50/15)• Mean age, range (years)* Safety population: treatment group 1 (5.5, 0.25 to 12); treatment group 2 (5.1, 0.5 to 12)* Efficacy population: treatment group 1 (6.4, 0.5 to 12); treatment group 2 (6.0, 0.5 to 12)• Sex (M/F)* Safety population: treatment group 1 (35/119); treatment group 2 (18/56)* Efficacy population: treatment group 1 (17/84); treatment group 2 (7/43)• Uropathy: treatment group 1 (28); treatment group 2 (9)• 52 APN included in safety; 36 in efficacy• Exclusion criteria: Cystitis episodes < 3/year; persistent UTI with uropathy; infections likely to need
treatments other than study drugs; antibiotics within last 2 weeks; other study drug in < 4 weeks; other
serious illness; pregnant, nursing or not using contraceptives; kidney abscess; history of hypersensi-
tivity.
Interventions Treatment group 1
• Oral ceCibuten: 9 mg/kg/d (max 400 mg/d) for 10 days
Treatment group 2
• Oral TMP/SMX: 8 mg/40 mg/kg/d (max 320/1600) for 10 days
Outcomes • Bacterial response at 5 to 9 days and 4 to 6 weeks after treatment completed• Clinical response at 5 to 9 days and 4 to 6 weeks after treatment completed• Adverse effects• Time to resolution of symptoms
Notes • Definition of APN not provided• 3/231 (1.3%) excluded from safety analysis. 80/231 (34.6%) excluded from efficacy (did not meet entry
criteria (51); mis-randomisation (6); efficacy data not available (18); other (5))
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Said to be randomly assigned. 2:1 ratio
Allocation concealment
(selection bias)
Unclear risk Said to be randomly assigned
Blinding of participants
and personnel (perfor-
mance bias) 
High risk No blinding and lack of blinding could influence clinical management
Banfi 1993 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding and lack of blinding could influence clinical outcome assessment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 16% of total group excluded from analysis for reasons other than not meeting
entry criteria and this could influence results
Selective reporting (re-
porting bias)
Low risk Data reported on clinical & bacteriologic response & adverse effects
Other bias Unclear risk No information provided
Banfi 1993  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 1995 to April 1999• Duration of follow-up: 3 months• Power analysis: 106/group to detect difference in rate of kidney scarring of 20%.
Participants • Country: Switzerland• Setting: multicentre (2), tertiary hospitals, IP• Children aged 3 months to 16 years with probable APN• Urine samples: bag, MSU, SPA• Number: treatment group 1 (111); treatment group 2 (118)• Median age, IQR (years): treatment group 1 (2.4, 0.8 to 5.6); treatment group 2 (1.0, 0.5 to 3.3 )• Sex (M/F): treatment group 1 (22/89); treatment group 2 (88/30)• Uropathy/VUR: treatment group 1 (42/36); treatment group 2 (44/40)• Exclusion criteria: allergy to cephalosporins; known uropathology
Interventions Treatment group 1
• IV ceftriaxone: 50 mg/kg daily for 3 days• Oral cefixime: 4 mg/kg/dose, 2 doses/d for 12 days (days 4 to 15)• Total 15 days
Treatment group 2
• IV ceftriaxone: 50 mg/kg daily for 10 days• Oral cefixime: 4 mg/kg/dose, 2 doses/d for 5 days (days 11 to 15)• Total 15 days
Outcomes • Scarring on DMSA at 3 months• Recurrent UTI at 3 months
Notes • Definition of APN: UTI and acute focal lesions on DMSA in patients with fever > 38°C, flank pain, con-
stitutional symptoms, CRP > 10 mg/L• 206/435 randomised were excluded as they had negative urine culture (84) or no acute pyelonephritis
changes on first DMSA (122)
Risk of bias
Benador 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Blocks of 20 sealed opaque envelopes with equal numbers of treatment as-
signments, stratified by centre
Allocation concealment
(selection bias)
Low risk Opaque sealed envelopes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome (DMSA scans) assessed by radiologists unaware of patient
assignment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 9 (8 in 10 day group, 1 in 3 day group) of 229 (4.4%) were excluded from results.
Unlikely to influence results
Selective reporting (re-
porting bias)
Low risk Reported expected outcomes + DMSA outcome
Other bias Unclear risk No information provided
Benador 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: August 2004 to April 2008 (recruitment)• Duration of follow-up: 6 to 8 months• Power analysis: 349/group to detect difference in rate of kidney scarring of 20%
Participants • Country: France• Setting: multicentre (10); hospital ED• Children aged 1 month to 36 months; first febrile UTI; temperature ≥ 38.5ºC; positive urine for WBC and
gram negative rods; pro-calcitonin ≥ 0.5 ng/mL; normal kidney ultrasound & pre-natal ultrasound; no
known uropathy• Urine samples: bag, MSU, SPA• Number: treatment group 1 (85); treatment group 2 (86)• Mean age ± SD (years): treatment group 1 (8.9 ± 6); treatment group 2 (10.6 ± 7.6)• Sex (M/F): treatment group 1 (34/51); treatment group 2 (25/61)• Uropathy (VUR): treatment group 1 (18); treatment group 2 (22)• Exclusion criteria* Primary: allergy to study medications; severely ill children; vomiting and/or diarrhoea precluding
oral medication; uncertain adherence; received antibiotic therapy in 5 days before inclusion* Secondary: normal DMSA; procalcitonin < 0.5 ng/mL, urine culture negative or > 1 organism or re-
sistant to study drugs; recurrence of APN before 2nd DMSA
Interventions Treatment group 1
• Oral cefixime: 8 mg/kg single dose, then oral 4 mg/kg/dose twice daily for 10 days
Treatment group 2
Bocquet 2012 
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• IV ceftriaxone: 50 mg/kg daily for 4 days• Oral cefixime: 4 mg/kg/dose twice daily for 6 days (days 5 to 10)
Outcomes • Scarring on DMSA at 6 months• Resolution of fever• Adverse effects
Notes • Definition of APN: UTI and acute focal lesions on DMSA in patients with fever > 38.5°C, procalcitonin
≥ 0.05 ng/mL• ITT population included in analysis• 52/171 (30%) excluded for no APN on DMSA (25), no DMSA (2), protocol violation (5), withdrawal of
consent (8), problems with obtaining results of MSU (10) or procalcitonin (2)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Computer generated code (Clean Web)". Blocked and stratified by centre and
age (≤ 1 year/> 1 year)
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Clinical management could be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome (DMSA scans) assessed without knowledge of treatment as-
signment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 18.5% (27/146) excluded for reasons other than no APN on acute DMSA
Selective reporting (re-
porting bias)
High risk No report on bacteriologic resolution of UTI
Other bias Low risk Ministry of Health via Unit of Clinical Research, Necker Hospital, grant PHRC
no. AOM 04 105
Bocquet 2012  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1999 to June 2003• Duration of follow-up: 6 to 9 months• Power analysis: 493 participants to detect difference in rate of kidney scarring of 10%
Participants • Country: France• Setting: multicentre (17) hospital IP• Children aged 3 months to 16 years; temperature > 38ºC; positive urine for nitrite, WBC, bacteriuria >
105/mL, CRP > 20 mg/L; no known uropathy• Urine samples: bag, MSU, SPA
Bouissou 2008 
Antibiotics for acute pyelonephritis in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
35
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Number (randomised/analysed): treatment group 1 (277/205); treatment group 2 (271/178)• Mean age, range (months): treatment group 1 (37, 3 to 191); treatment group 2 (31, 3 to 131)• Sex (M/F): treatment group 1 (33/172); treatment group 2 (53/125)• Uropathy (VUR): treatment group 1 (73); treatment group 2 (70)• Exclusion criteria* Primary: severely ill children; pseudomonas, staph or Group D Strep UTI; fever > 38ºC for > 4 days* Secondary: recurrence of APN before DMSA at 6 to 9 months; VUR > grade 3
Interventions Treatment group 1
• IV netilmicin: 7 mg/kg/d, days 1 and 2• IV ceftriaxone: 50 mg/kg/d, days 1, 2 and 3• Oral antibiotics: days 4 to 8 (5 days) according to sensitivity• Total 8 days
Treatment group 2
• IV netilmicin: 7 mg/kg/d, days 1 and 2• IV ceftriaxone: 50 mg/kg/d, days 1 to 8
Outcomes • Scarring on DMSA at 6 months
Notes • Definition of APN: UTI + fever > 38º, CRP > 20 mg/L• 165/548 (30%) excluded for loss to follow-up (87), APN recurrence (32), uropathy (16), No DMSA per-
formed (30)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation (random tables) was centralised and stratified by centre
by blocks of 20 numbered sealed opaque envelopes with equal numbers of
treatment assignments"
Allocation concealment
(selection bias)
Low risk Allocation was done by local investigator by opening a numbered sealed enve-
lope 48 hours after admission and after informed consent by the parents"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome (DMSA scan) assessed by 4 independent physicians without
knowledge of treatment assignment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 117/300 (23%) were lost to follow-up or refused DMSA after secondary exclu-
sions made. Could influence results
Selective reporting (re-
porting bias)
High risk No information on clinical or bacteriologic cure or adverse effects
Other bias High risk Supported by grants from Roche Laboratory and French Ministry of Health
Bouissou 2008  (Continued)
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Methods • Study design: parallel RCT• Study duration: March 1994 to January 1997• Duration of follow-up: 2 months• Power analysis: 87/group to show 1 day difference in fever duration
Participants • Country: Australia• Setting: tertiary centre IP• Children aged 1 month to 12 years; were ill, vomiting and unable to take oral medication reliably; UTI
was diagnosed by identifying uropathogens in suprapubic aspirate specimens or a pure growth of ≥
108 bacteria/L (= 105/mL)• Urine samples: MSU, catheter, SPA• Number: treatment group 1 (90); treatment group 2 (89)• Median age, IPR (years): treatment group 1 (1, 0.4 to 6.0); treatment group 2 (1, 0.4 to 4.6)• Sex (M/F): treatment group 1 (27/63); treatment group 2 (30/59)• Known uropathy/VUR detected: treatment group 1 (24/22); treatment group 2 (19/26)• Exclusion criteria: allergy to aminoglycoside, renal, hearing, vestibular dysfunction, neutropenia/im-
munodeficiency
Interventions Treatment group 1
• Daily IV gentamicin: < 5 years: 7.5 mg/kg/d; 5-10 years: 6 mg/kg/d; > 10 years: 4.5 mg/kg/d; for 3.0 days
(range 2 to 4)
Treatment group 2
• IV gentamicin: same total dose each day as group 1 but given in three divided doses for 2.7 days (range
2 to 3.3)
Outcomes • Resolution of clinical problem• Infective or non-infective sequelae• Persistent bacteriuria at end of gentamicin• Adverse effects
Notes • Definition of APN: UTI and fever, vomiting, inability to take oral therapy• 5/184 excluded because did not satisfy entry criteria. None of 179 excluded from clinical analysis;
60/179 (33.5%) did not have follow-up urine culture & excluded from bacteriological outcome assess-
ment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation stratified for age < 2 years and ≥ 2 years
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label study. Knowledge of treatment group could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open label study. Primary outcome of clinical response could be influenced
by knowledge of treatment group. "Audiology, bacteriology and biochemistry
personnel were blinded to treatment status"
Carapetis 2001 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk None of 179 excluded from primary outcome of clinical response
Selective reporting (re-
porting bias)
Low risk Reported expected outcomes (clinical and bacteriologic eradication, adverse
effects)
Other bias Unclear risk No information provided
Carapetis 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 2003 to December 2004• Duration of follow-up: 6 months• Power analysis: NS
Participants • Country: Taiwan• Setting: tertiary centre IP• Children aged 0 months to 16 years; UTI plus CT findings of lobar nephronia following US showing
nephromegaly and/or focal renal mass• Urine samples: most collected by MSU, SPA or catheter• Number: treatment group 1 (39); treatment group 2 (41)• Mean age ± SD (years): treatment group 1 (4.16 ± 4.22); treatment group 2 (3.72 ± 4.14)• Sex (M/F): treatment group 1 (16/23); treatment group 2 (17/24)• VUR detected: treatment group 1 (11/29); treatment group 2 (16/40)• Exclusion criteria: uncomplicated APN
Interventions Treatment group 1
• 3 weeks duration of IV and oral antibiotics• Antibiotic used depended on sensitivities• IV changed to oral 2 to 3 days after fever had ceased
Treatment group 2
• 2 weeks duration of IV and oral antibiotics• Antibiotic used depended on sensitivities• IV changed to oral 2 to 3 days after fever had ceased
Outcomes • Bacteriological persistent/relapse• Persistence/recurrence of symptoms• Duration of fever
Notes • Lobar nephronia (acute focal bacterial nephritis) diagnosed on CT but specific findings NS• Information from the authors: All children completed follow-up. Information on risk of bias
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk "Randomly allocated with serial entry"
Cheng 2006 
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Allocation concealment
(selection bias)
High risk Patients allocated alternately to each group (information from the authors)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding. Lack of blinding could influence outcome assessment of clinical
symptoms
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No loss to follow-up. Information confirmed by authors
Selective reporting (re-
porting bias)
High risk No reporting of adverse effects. Incomplete data on clinical symptom resolu-
tion
Other bias Unclear risk No information provided
Cheng 2006  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 2000 to May 2001• Duration of follow-up: 3 months• Power calculation: 220 to show 10% difference in UTI cure with 80% power
Participants • Country: Singapore• Setting: tertiary centre IP• Children aged I month to 13 years; UTI confirmed on 2 clean catch urine samples (single organism >
100,000/mL) or 1 catheter specimen (single organism > 1,000/mL)• Number: treatment group 1 (84); treatment group 2 (88)84 (40F)• Mean age ± SD (years): treatment group 1 (0.95 ± 1.25); treatment group 2 (0.90 ± 1.36)• Sex (M/F): treatment group 1 (44/40); treatment group 2 (41/47)• VUR: treatment group 1 (21, 11 no MCU); treatment group 2 (21, 15 no MCU)• Exclusion criteria: known obstructive uropathy; aminoglycoside or other nephrotoxic agent in previ-
ous month; allergy to aminoglycoside; renal or hearing impairment (including abnormal baseline OAE)
Interventions Treatment group 1
• IV gentamicin: 5 mg/kg/d daily till resolution of fever (3.7 ±1.8 days)
Treatment group 2
• IV gentamicin: 6 mg/kg/d 8 hourly till resolution of fever (3.5 ± 1.8 days)
Outcomes • Negative urine culture at end of gentamicin• Time to resolution of fever• Nephrotoxicity (increase in creatinine by 50% or more)• Ototoxicity (loss of 30 dB or more on repeat OAE test and confirmed on brain auditory evoked response• Kidney scars on DMSA scan at 3 months
Notes • Definition of UTI: fever > 38°C, pyuria > 200/mL or offensive urine, dysuria, frequency, loin pain
Chong 2003 
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• Post randomisation exclusions: No UTI (23), protocol violation (10), abnormal baseline OAE hearing
test• 38/210 excluded from analysis: no UTI (23); resistant to gentamicin (1); abnormal baseline hearing (4);
protocol violation (10)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding but primary outcome was a laboratory result (negative urine cul-
ture) and unlikely to influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 15 (8%, excluding patients without UTI) were excluded from analysis (not in-
cluding patients without UTI). This is unlikely to influence results
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported
Other bias Low risk Funded by KK Women's and Children's Hospital RAU Grant 029/1999
Chong 2003  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 21 days• Power calculation: NS
Participants • Country: France• Setting: tertiary centre IP• Children presenting with UTI (urinary leucocyte count >10 WBC/mm3 and bacteriuria greater than or
equal to 100,000 colonies/mL); a predominant isolate (more than 80% of the flora), with tissue pene-
tration; clinically poor general condition; lumbar or abdominal pain; temperature > 38.5°C; ESR > 35
mm at 1 h; elevated CRP and orosomucoid• Urine collection: NS• Number: treatment group 1 (10); treatment group 2 (10)• Age: treatment group 1 (≤ 6 years (6); > 6 years (4)); treatment group 2 (≤ 6 years (6); > 6 years (4))• Sex (M/F): treatment group 1 (3/7); treatment group 2 (2/8)• Known uropathy: treatment group 1 (1); treatment group 2 (1)• Exclusion criteria: allergy to B-lactam antibiotics; UTI post operatively; antibiotics in previous 72
hours; creatinine > 0.2 mmol/L
Fischbach 1989 
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Interventions Treatment group 1
• IV cefotaxime: 25 mg/kg/dose, 4 doses/d for 14 days
Treatment group 2
• IV amox/clav: 25 mg/kg/dose, 4 doses/d for 1 to 7• Oral amox/clav: 50 mg/kg/d days 8 to 14
Outcomes • Time to fever resolution• Persistent bacteriuria at 48 to 72 hours• Recurrent UTI at 7 days after completing therapy
Notes • Definition of APN: UTI and fever > 38.5°C, loin pain, poor clinical condition, elevated CRP, ESR
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation table used
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding and clinical management could be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding and primary clinical outcome assessment could be influenced by
lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed follow-up
Selective reporting (re-
porting bias)
Low risk All expected outcomes are included
Other bias Unclear risk No information provided
Fischbach 1989  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration:• Duration of follow-up: 1 month• Power calculation: NS
Participants • Country: France• Setting: multicentre tertiary centres IP• Children aged 6 months to 10 years• Urine collection: NS• Number (randomised/efficacy/safety): treatment group 1 (70/63/67); treatment group 2 (77/65/72)
Francois 1997 
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• Mean age ± SD (years): treatment group 1 (3.9 ± 2.9); treatment group 2 (4.3 ± 2.7)• Sex (M/F): treatment group 1 (6/57); treatment group 2 (8/57)• VUR: treatment group 1 (26); treatment group 2 (25)• Exclusion criteria: Previous APN; organisms resistant to study antibiotics; allergy to cephalosporins, B-
lactams, aminoglycosides; known uropathology; need for IV antibiotics based on ultrasound; kidney
failure; immune deficiency; other infection
Interventions Treatment group 1
• IV ceftriaxone: 50 mg/kg/d, daily dose for days 1 to 4• IV netilmicin: 6 to 7.5 mg/kg/d in 3 divided doses for days 1 to 4• Oral cefixime: 4 mg/kg/dose, 2 doses/d for days 5 to 10
Treatment group 2
• V ceftriaxone: 50 mg/kg/d, daily dose for days 1 to 4• IV netilmicin: IV 6 to 7.5 mg/kg/d in 3 divided doses for days 1 to 4• IV ceftriaxone: 50 mg/kg/d as single dose for days 5 to 10
Outcomes • Persistent bacteriuria 2 days after end of therapy• Recurrent UTI in 20 days after therapy• Adverse events
Notes • Definition of APN: UTI and fever > 38°C, pyuria, CRP increased• 19/147 (13%) excluded from efficacy analysis as did not have UTI
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated random list
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Clinical management and assessment could be influenced by
blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding but outcomes evaluated by a scientific committee so unlikely to
be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients with positive urine cultures evaluated for efficacy
Selective reporting (re-
porting bias)
Low risk Expected outcomes included
Other bias Unclear risk No information provided
Francois 1997  (Continued)
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Methods • Study design: parallel RCT• Study duration: unclear• Duration of follow-up: unclear• Power analysis: NS
Participants • Country: Japan• Setting: multicentre tertiary centres IP• Urine collection: NS• Number: treatment group 1 (54); treatment group 2 (51)• Age: NS• Sex (M/F): NS• Exclusion criteria: NS
Interventions Treatment group 1
• Ampicillin suppositories: 1 g, 6 hourly for 5 days
Treatment group 2
• Oral ampicillin: 1 g, 6 hourly for 5 days
Outcomes • Clinical response• Eradication of causative organism
Notes • APN: not defined• Abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No blinding and unclear whether clinical or laboratory outcomes were primary
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Expected outcomes reported
Selective reporting (re-
porting bias)
Unclear risk No information provided
Other bias Unclear risk No information provided
Fujii 1987 
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Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 6 weeks• Power analysis: NS
Participants • Country: New Zealand• Setting: tertiary centre IP and OPD• Urine collection: SPA or 2 consecutive MSU• Number: treatment group 1 (39); treatment group 2 (30)• Mean age (range): 4.9 years (range 2 weeks to 12 years)• Sex (M/F): 17/52• Uropathy/VUR: 26/10• APN: treatment group 1 (14); treatment group 2 (10)• Exclusion criteria: NS
Interventions Treatment group 1
• IV gentamicin: 3 mg/kg single dose
Treatment group 2
• 7 days of antibiotic according to sensitivity: TMP/SMX (16); amoxicillin (11); cephalosporins (3)
Outcomes • Persistent bacteriuria 1 day after therapy• Relapse within 1 week of end of therapy• Recurrent UTI 1-6 weeks after end of therapy
Notes • Definition of APN: UTI and fever > 38°C, loin pain, systemic effects• Study included 24 children with APN and 45 with cystitis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Each child was randomly allocated by random numbers to two treatment
groups". Not stratified by clinical presentation
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding but primary outcome was laboratory based and unlikely to be in-
fluenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed study
Selective reporting (re-
porting bias)
High risk No results provided on clinical resolution or adverse events
Grimwood 1988 
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Other bias Low risk National Children's Health Research Foundation
Grimwood 1988  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1992 and July 1997• Duration of follow-up: 7 months• Power calculation: 128/group to detect difference of 15% in kidney scarring
Participants • Country: USA• Multicentre (3) tertiary centre IP and ED• Children aged 1 month to 2 years; rectal temperature of ≥ 38.3°C at presentation or within 24 hours,
were suspected to have a UTI because of the presence of pyuria and bacteriuria; a positive urine cul-
ture from a specimen obtained by catheter• Urine collection: catheter• Number: treatment group 1 (153); treatment group 2 (153)• Mean age ± SD (years): treatment group 1 (8.8 ± 5.9); treatment group 2 (8.3 ± 5.6)• Sex (M/F): treatment group 1 (17/136); treatment group 2 (16/137)• VUR: treatment group 1 (61); treatment group 2 (54)• Exclusion criteria: clinically unstable patients; previous UTI; known uropathy; allergy to
cephalosporins; other infections; gram positive cocci on stained urine
Interventions Treatment group 1
• Oral cefixime: 16 mg/kg on day 1 then 4 mg/kg/dose, 2 doses/d for 13 days
Treatment group 2
• IV cefotaxime: 50 mg/kg/dose, 4 doses/d for 3 days or till afebrile for 24 hours• Oral cefixime: 16 mg/kg following IV cefotaxime for 1 day then 4 mg/kg/dose, 2 doses/d for 13 days
Outcomes • Scarring on DMSA at 6-7 months after UTI• Recurrent UTI in 6 months• Duration of fever
Notes • Definition of APN: UTI and fever > 38.3°C
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Subjects were randomized at each site based on age and duration of fever"
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Clinical management could be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
Low risk Blinding of radiologists, who assessed DMSA scans. Short term outcome (urine
culture) was laboratory based and unlikely to be affected by blinding
Hoberman 1999 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 34/306 (11%) no follow-up DMSA scans
Selective reporting (re-
porting bias)
High risk No information on adverse effects
Other bias High risk Supported by Lederle/Wyeth-Ayerst Laboratories and by NIH grants
Hoberman 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 6 months• Power calculation: NS
Participants • Country: Greece• Setting: tertiary centre IP• Children aged 1 month to 12 years; APN requiring IV antibiotics• Urine collection: SPA, catheter or 2 clean catch specimens• Number: Treatment group 1 (10): treatment group 2 (6)• Median age (range): 3 months (1 to 84 months)• Sex (M/F): 6/10• Uropathy: 4• Exclusion criteria: allergy to aminoglycosides, renal, hearing or vestibular dysfunction, antibiotics in
previous 4 weeks, resistance to aminoglycosides
Interventions Treatment group 1
• IV isepamicin: 7.5 mg/kg/dose, 2 doses/d for 10 to 14 days
Treatment group 2
• IV amikacin: 7.5 mg/kg/dose, 2 doses/d for 10 to 14 days
Co-interventions
• Both agents were administered either solely or in combination with an appropriate antimicrobial
agent
Outcomes 1. Persistent bacteriuria 7 days after end of therapy.
2. UTI 30 days after end of therapy.
3. Adverse events.
Notes • Definition of APN: UTI and fever > 38°C, systemic or local symptoms, CRP > 30 mg/L, elevated ESR,
WBC, pyuria
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided. 2:1 ratio
Kafetzis 2000 
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Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary efficacy outcome was laboratory based and unlikely to be influenced
by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed study
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported
Other bias High risk Sponsored by Schering-Plough Research
Kafetzis 2000  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 2 months• Power calculation: No
Participants • Country: USA• Setting: tertiary centre, OPD• Children aged 6 month to 15 years• Urine collection: 2 consecutive clean catch specimens with positive culture (> 105 CFU/mL)• Number: treatment group 1 (27); treatment group 2 (27)• Mean age ± SEM (years): treatment group 1 (5.5 ± 0.6); treatment group 2 (5.8 ± 0.5)• Sex (M/F): treatment group 1 (2/25); treatment group 2 (2/25)• Exclusion criteria: urinary tract malformation or abnormal creatinine
Interventions Treatment group 1
• Oral antibiotic: ampicillin, cephalexin or sulphisoxazole 4 times/d for 3 days
Treatment group 2
• Oral antibiotic: ampicillin, cephalexin or sulphisoxazole 4 times/d for 10 days
Outcomes • Absence of recurrence by 2 months (bacteriological)• Recurrence of UTI within 2 months
Notes • Definition of APN: temperature > 38°C with/without other symptoms
Risk of bias
Bias Authors' judgement Support for judgement
Khan 1981 
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Random sequence genera-
tion (selection bias)
High risk Episodes of UTI "treated prospectively on a random basis alternately"
Allocation concealment
(selection bias)
High risk Episodes of UTI "treated prospectively on a random basis alternately"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment. Patients ret-
rospectively divided into APN, lower UTI or asymptomatic
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary efficacy outcome was laboratory based and unlikely to be influenced
by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if all patients completed the study
Selective reporting (re-
porting bias)
High risk No information on adverse effects. Data only available as the number of
episodes of APN
Other bias Unclear risk No information provided
Khan 1981  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: December 1995 to December 1998• Duration of follow-up: 6 months• Power calculation: NS
Participants • Country: Belgium• Setting; tertiary centre, IP/OPD• Children aged 6 weeks to 15 years; severely ill; fever ≥ 38.3°C associated with variable combinations of
clinical signs ; biological alterations (sedimentation rate > 30 mm/h, increased CRP, leukocyte count
> 15,000 with more than 50% neutrophils), and urinalysis revealing abnormal amounts of leukocytes
(> 5 WBC/mm3) and/or bacteria; absence of other focal infection• Urine collection: SPA, MSU, 2-3 consecutive bag specimens• Number: treatment group 1 (43); treatment group 2 (44)• Median age, range (months): treatment group 1 (25, 2 to 182); treatment group 2 (20, 3 to 179)• Sex (M/F): NS• Uropathy: treatment group 1 (5); treatment group 2 (1)• Exclusion criteria: negative urine culture; resistant organisms; severe uropathies; fever > 38°C within
24 hours of randomisation
Interventions Both groups given temocillin IV 3 days and then randomised
Treatment group 1
• IV temocillin: for further 4 days; dose (NS)• Oral amoxicillin or amox/clav: 50 mg/kg/dose, 3 doses/d for further 14 days
Treatment group 2
• Oral amoxicillin or amox/clav: 50 mg/kg/dose, 3 doses/d for 18 days
Levtchenko 2001 
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Outcomes • Persistent bacteriuria on day 7 of treatment• Recurrent UTI in 6 weeks after randomisation• Persistence of changes on DMSA at 6 months
Notes • Definition of APN: UTI and fever > 38.3°C at start of IV therapy (afebrile at randomisation), systemic
symptoms, loin pain, elevated WBC, ESR, CRP• 5 (5.4%) of 92 patients were excluded: intolerance to oral medication (1), error in randomisation (1),
no follow-up at 6 months (3)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Clinical assessment could be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding
Primary outcome of kidney scarring; DMSA scans reviewed without knowledge
of treatment assignment.
Primary outcome of urine culture: laboratory based and unlikely to affected by
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 5 (5.4%) of patients did not complete follow-up. Unlikely to influence outcome
Selective reporting (re-
porting bias)
High risk No detailed information on clinical response or adverse effects
Other bias Unclear risk No information provided
Levtchenko 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 1996 to February 2001• Duration of follow-up: 30 days• Power calculation: 256 and 128 required for each group for a difference in treatment response ≤ 8%
Participants • Country: Sweden• Setting: multicentre (7) tertiary IP/OPD• Children aged 1 month to 12 years; first febrile UTI; Fever ≥ 38.5º in last 24 hours with/without abdom-
inal pain, vomiting, flank pain; CRP ≥ 20 mg/L• Urine collection: SPA, MSU, bag specimens• Number: treatment group 1 (255); treatment group 2 (128)• Median age, range (years): treatment group 1 (0.9, 0.09 to 10.6); treatment group 2 (0.8, 0.09 to 7.3)
Marild 2009 
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• Sex (M/F): treatment group 1 (187/68); treatment group 2 (90/38)• Exclusion criteria: Previous treatment for UTI; antibiotics in previous 7 days; needing IV therapy;
known uropathy; hypersensitive to medications
Interventions Treatment group 1
• Oral ceCibuten: 9 mg/kg once/d for 10 days
Treatment group 2
• Oral TMP/SMX: 3 mg/15 mg/kg twice/d for 10 days
Outcomes • Bacteriological elimination after treatment without recurrence• Clinical resolution• Adverse events
Notes • APN: Fever ≥ 38.5º, abdominal pain, vomiting, flank pain, CRP ≥ 20 mg/L• Primary exclusions: 127/547 (23%) excluded (no bacteriuria 101, did not fulfil entry criteria 26)• Secondary exclusions: 37/420 (9%) not evaluable (no follow-up (29), on prophylaxis (8))• ITT population 255/128. PP population 228/102
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated block randomisation stratified by gender. 2:1 allocation
Allocation concealment
(selection bias)
Low risk Sealed envelopes containing assigned treatment and randomisation number
were opened in numerical order for eligible study patients
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label study. Lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Clinical outcome assessment could be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 9% of 420 patients excluded. Unlikely to influence results
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported
Other bias High risk Supported by grant from Schering-Plough
Marild 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 2000 to July 2005• Duration of follow-up: 12 months• Power calculation: 220/group for 10% difference between groups
Montini 2007 
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Participants • Country: Italy• Setting: multicentre tertiary centres (28)• Children aged 1 month to < 7 years; first episode of APN; normal antenatal ultrasound; 2 concordant
urinalyses (> 25 WBC/µL) and 2 concordant urine cultures (> 100,000 CFU/mL) collected in sterile bags;
at least 2 of fever ≥ 38ºC, ESR ≥ 30 mm, CRP ≥ 3 times upper limit of normal, neutrophil count > normal
for age• Number* Evaluated for short-term outcomes: treatment group 1 (244); treatment group 2 (258)* Completed the study: treatment group 1 (197); treatment group 2 (203)* Repeat DMSA: treatment group 1 (109); treatment group 2 (114)• Mean age ± SD (months): treatment group 1 (12.7 ± 14.2); treatment group 2 (11.9 ± 13.9)• Sex (M/F): treatment group 1 (85/159); treatment group 2 (95/163)• Exclusion criteria: Severe clinical sepsis; dehydration, vomiting; allergy to study drugs; creatinine
clearance < 70
Interventions Treatment group 1
• Oral amox/clav: 50 mg/kg/d in three doses for 10 days
Treatment group 2
• IV ceftriaxone: 50 mg/kg/d till resolution of fever• Oral amox/clav: 50 mg/kg/d to complete 10 day course
Outcomes • Kidney parenchymal damage on DMSA scan at 1 year• Time to fever defervescence• Number with persistent bacteriuria at 72 hours• WBC, ESR, CRP at 72 hours
Notes • Definition of APN: fever ≥ 38°C, high inflammation indices (WBC > normal for age, ESR ≥ 30 mm/h, CRP
≥ 3 times normal for age)• Children with no kidney parenchymal defects on first DMSA scan were not re-scanned at 1 year and
assumed to have no scars at 1 year• Loss to follow-up: 102 (20.3%) of 502 did not complete study (13 did not have DMSA at entry, 89 did
not undergo indicated DMSA at follow-up)• 177 patients with negative DMSA at entry, did not undergo follow-up scan and assumed to have no
scar at follow-up
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated block randomisation with stratification by hospital, sex,
age (< 2 years; ≥ 2years) at coordinating centre
Allocation concealment
(selection bias)
Low risk "Each participating centre received 4 series of 10 allocation codes in sealed
and sequentially numbers opaque envelopes. The sequence was concealed
until interventions assigned. Each participating centre allocated the children
following a numeric order"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical assessment. "Could not
blind group assignment because of the different routes of administration of
the drug"
Blinding of outcome as-
sessment (detection bias) 
Low risk Primary outcome was scarring on DMSA at 12 months. "Two nuclear physi-
cians blinded to test results interpreted the scans independently"
Montini 2007  (Continued)
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Loss to follow-up was 20.3% and could influence results
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported
Other bias Low risk Region of Veneto (research project 40/01) and Association Il Sogno di
Stephano
Montini 2007  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 1 July 2004 to 31 December 2004• Duration of follow-up: 6 months• Power calculation: 98/group for 20% difference between groups
Participants • Country: Switzerland.• Setting: multicentre tertiary hospital IP/OPD (5)• Children aged 6 months to 16 years; fever > 38.5º; abnormal urinalysis; with/without abdominal or
flank pain; irritability; vomiting; diarrhoea; feeding difficulties. Included 152 with acute DMSA lesions
who were evaluated with follow-up DMSA scans. Patients subsequently found not to have UTI or APN
on DMSA were excluded• Urine collection: catheter• Number: treatment group 1 (80); treatment group 2 (72)• Median age, IQR (years): treatment group 1 (2.2, 0.9 to 4.9); treatment group 2 (1.6, 1.0 to 4.4)• Sex (M/F): treatment group 1 (8/72); treatment group 2 (10/62)• Exclusion criteria: complex kidney malformations; septic appearance; allergies to cephalosporins; im-
munosuppressive agents; impaired kidney function
Interventions Treatment group 1
• Oral ceCibuten: 9 mg/kg once daily for 14 days
Treatment group 2
• IV ceftriaxone: 50 mg/kg once daily for 3 days• Oral ceCibuten: 9 mg/kg once daily for 11 days
Outcomes • Persistent lesions on second DMSA• Fever at day 3• Resolution of UTI
Notes • APN: UTI, fever 38°C , CRP > 10 mg/L, DMSA acute lesions• Primary exclusions: 146/365 (40%); no acute DMSA (19), no APN on DMSA (127)• Secondary exclusions: 67/219 (30%) for no follow-up DMSA• Additional information on methodology obtained from authors• Register of Swiss National Agency for therapeutic products Trial Number IKS 2001S03204
Risk of bias
Bias Authors' judgement Support for judgement
Neuhaus 2008 
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Random sequence genera-
tion (selection bias)
Low risk Computer generated code. Independent clerk sealed and bundled blocks of 24
opaque sealed envelopes containing an equal number of assignments provid-
ed to centres
Allocation concealment
(selection bias)
Low risk Opaque sealed envelopes "so that people enrolling the patient into the study
would not have known patient's assignment"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk DMSA scans read by investigators without knowledge of assignments
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 67/219 (30%) excluded from analysis as had no FU DMSA. This could influence
results
Selective reporting (re-
porting bias)
High risk No report of adverse effects
Other bias High risk Financial support from the Essex Company
Neuhaus 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: February 2003 to June 2003• Duration of follow-up: 6 weeks• Power calculation: NS
Participants • Country: Iran• Setting: single tertiary centre• Children aged 1 to 10 years; need for IV therapy; pathogen susceptible to study drug• Urine collection: strap on bags for infants; clean catch urine samples for older children• Number: treatment group 1 (24); treatment group 2 (30)• Age: NS• Sex (M/F): 11/43• Exclusion criteria: allergy to study drugs; kidney obstruction/abscess; severe underlying disease/im-
munosuppressive therapy; other antibiotics required; abnormal LFTs/FBC; treated with IV antibiotics
for 24 hours plus within 72 hours of baseline MSU; CKD stages 4, 5
Interventions Treatment group 1
• IV ceftriaxone 50 mg/kg/d for 2 to 3 days• Oral cefixime: 8 mg/kg/d for 8 days
Treatment group 2
• IV Amikacin 15 mg/kg/d or IV gentamicin 3 mg/kg/d with IV ampicillin 100 mg/kg/d for 10 days
Outcomes • Clinical response at 3 to 5 days, end of therapy, 5 to 9 days after end of therapy and 4 to 6 weeks• Failure at 48 to 72 hours of therapy (urine culture with 10,000 organisms/mL of admission organism)
Noorbakhsh 2004 
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Notes • APN: culture > 100,000 CFU/mL, fever, flank pain, costovertebral angle tenderness• Four patients did not complete follow-up and were not included in the study• Additional information obtained from authors on allocation concealment, follow-up and study defi-
nitions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Children were allocated alternately to each group (information from authors)
Allocation concealment
(selection bias)
High risk Children were allocated alternately to each group (information from authors)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management. "After 2-3
days of parenteral study therapy, investigators had the option to switch to oral
cefixime if the patients had clinically improved". Unclear whether this referred
to both treatment groups or whether patients in Group 1 could be continued
on IV therapy for a longer duration.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding. Primary outcome of clinical response could be influenced by lack
of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 4 (7%) patients did not complete follow-up and were excluded from the study
Selective reporting (re-
porting bias)
High risk No report on adverse effects
Other bias High risk Pharmacist employed by Exir Pharmaceutical Co is study author
Noorbakhsh 2004  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 12 months• Power calculation: NS
Participants • Country: Finland• Setting: tertiary centre OPD• Children aged 0 to 13 years; 149 with upper tract UTI, 86 lower UTI (symptomatic (72); asymptomatic
(14)• Urine collection: SPA or 2 consecutive MSU• Uropathy: 8• Number: treatment group 1 (121); treatment group 2 (114)• Age: NS• Sex: NS• APN: treatment group 1 (73); treatment group 2 (76)• Exclusion criteria: NS
Interventions Treatment group 1
Pylkkänen 1981 
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• Oral sulfafurazole: 150 to 200 mg/kg/d in 3 doses for 10 days
Treatment group 2
• Oral sulfafurazole: 150 to 200 mg/kg/d in 3 doses for 42 days
Outcomes • Recurrent UTI during 12 months• Recurrent UTI by 1 month after ceasing therapy
Notes • Definition of APN: UTI and fever > 39°C, ESR > 35, CRP > 20 mg/L• 271 entered study (10 lost to follow-up; 9 did not comply); 252 completed 2 years of follow-up of whom
235 (93%) evaluated (excluded - abnormal IVP (15); treatment error (2))
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided. Not stratified for APN. "Patients were randomly di-
vided.."
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding. Primary outcome was laboratory based and unlikely to be influ-
enced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 36/271 (13%) excluded.
Selective reporting (re-
porting bias)
High risk No report of clinical resolution or adverse effects
Other bias High risk Supported by Foundation for Pediatric Research, Sigrid Juselius Foundation,
Orion Pharmaceutical Co.
Pylkkänen 1981  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 6 weeks• Power calculation: NS
Participants • Country: Argentina• Setting: tertiary centre OPD• Children aged 1 month to 14 years; first or recurrent UTI• Urine collection: SPA, MSU• Number: treatment group 1 (18); treatment group 2 (19)18 (17F)• Median age (years): treatment group 1 (5); treatment group 2 (6)
Repetto 1984 
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• Sex (M/F): treatment group 1 (2/16); treatment group 2 (4/15)• Uropathy: treatment group 1 (2); treatment group 2 (2)• APN: treatment group 1 (4); treatment group 2 (7)• Exclusion criteria: allergy to cephalosporins or penicillins; kidney failure; major uropathy
Interventions Treatment group 1
• IV cefotaxime: 50 mg/kg single dose
Treatment group 2
• Appropriate oral antibiotic for 10 days: TMP/SMX (14), nalidixic acid (2) nitrofurantoin (2), cephalexin
(1), gentamicin (1)
Outcomes • Persistent bacteriuria at 48 hours after end of treatment• Recurrent UTI at 30 days
Notes • Definition of APN: UTI and fever > 38°C, loin pain• All participants completed follow-up
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided. "Patients..were treated randomly with either...). Not
stratified for APN
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding. Primary outcomes were clinical and laboratory based. Clinical
outcomes could be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants completed the study
Selective reporting (re-
porting bias)
High risk No clinical outcomes reported
Other bias Unclear risk No information provided
Repetto 1984  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: February 1996 to February 1997• Duration of follow-up: 6 weeks• Power calculation: 150 patients/group to ensure difference in eradication rates < 12.6%
Participants • Country: Europe (13 countries)
Schaad 1998 
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• Setting: multicentre tertiary centres IP (39)• Children aged ≥1 month to 12 years; fever of at least 38.5°C; WBC > 15.000/mL; CRP > 30 µg/mL; evi-
dence of pyuria; aged > 2 years to have one of the following: abdominal pain or tenderness, flank pain;
or tenderness and dysuria• Urine collection: SPA, catheter, MSU, 2 consecutive bags• Number: treatment group 1 (149); treatment group 2 ()• Evaluated for efficacy: treatment group 1 (115); treatment group 2 (120)• Median age, range (years): treatment group 1 (1.7, 0.1 to 12.9); treatment group 2 (1.8, 0.1 to 11.8)• Sex (M/F): treatment group 1 (32/83); treatment group 2 (37/83)• Uropathy/VUR: treatment group 1 (53/33); treatment group 2 (56/33)• Exclusion criteria: weight < 3 kg; previous investigational drug; allergy to B-lactams or arginine; kidney
or liver dysfunction; immune deficiency
Interventions Treatment group 1
• IV cefepime: 50 mg/kg/dose, 3 doses/d till afebrile for 48 hours• Oral TMP/SMX for 10 to 14 days or further IV therapy
Treatment group 2
• IV ceftazidime: 50 mg/kg/dose, 3 doses/d till afebrile for 48 hours• Oral TMP/SMX for 10 to 14 days
Outcomes • Persistent bacteriuria and unsatisfactory clinical response at end of IV therapy, end of antibiotic ther-
apy• Recurrent UTI and unsatisfactory clinical response at 5 to 9 days and 4 to 6 weeks after end of therapy• Adverse effects
Notes • Definition of APN: UTI and fever ≥ 38.5°C, WBC > 15,000 or CRP > 30 µg/mL and 1+ abdominal pain, loin
pain, dysuria in children > 2 years• 299 enrolled; all assessed for safety; 235 evaluated for efficacy; 64 (21%) excluded from efficacy (no
pathogen (40); treatment shorter than 12 days (13); improper dose (7): other (4))
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stratified by age (1 month to 2 years; > 2 years)
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management. "Study
drugs were administered in an open label manner"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Individual results were evaluated by blinded committee of experts"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 40/299 excluded for no pathogen; 24/259 (9%) excluded for other reasons but
should have been included in analysis. 9% exclusions unlikely to influence out-
comes. All patients included in safety analysis
Schaad 1998  (Continued)
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Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Biostatistics and data management by Bristol-Myers Squibb. Grant from Bris-
tol-Myers Squibb
Schaad 1998  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 5 weeks• Power calculation: NS
Participants • Country: Brazil• Setting: Tertiary centre IP/OPD• Children aged 2 to 14 years; proven bacteriuria; at least 2 of the following: fever, dysuria, flank tender-
ness, urgency, and pyuria• Urine collection: MSU - 2 consecutive specimens• Number: treatment group 1 (26); treatment group 2 (11)• Age: treatment group 1 (); treatment group 2 ()• Sex (M/F): treatment group 1 (10/16); treatment group 2 (3/8)• VUR: 6• Exclusion criteria: resistant organisms; kidney or liver dysfunction; allergy to B-lactam antibiotics
Interventions Treatment group 1
• Oral cefetamet pivoxil: 10 mg/kg/dose (18) or 20 mg/kg/dose (8), 2 doses/d for 7 to 10 days
Treatment group 2
• Oral amox/clav: 30 to 50 mg/kg/dose, 3 doses/d for 7 to 10 days
Outcomes • Persistent bacteriuria or unsatisfactory clinical response at end of therapy and at 4 to 5 weeks• Adverse effects
Notes • Definition of APN: UTI and 2 + of fever ≥ 37.5°C, loin tenderness, dysuria, pyuria• Follow-up: all participants completed follow-up
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation list
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Toporovski 1992 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical outcome assessment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed follow-up
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Supported by F. Hoffman-La Roche Ltd
Toporovski 1992  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: 6 weeks• Power calculation: Sample size chosen to detect 20% difference in effectiveness
Participants • Country: Italy• Setting: tertiary centre IP• Children aged 1 month to 12 years; documented UTI and signs of pyelonephritis• Urine collection: clean catch or catheter• Number: treatment group 1 (74); treatment group 2 (70)• Mean age ± SD (years): treatment group 1 (2.01 ± 2.23); treatment group 2 (1.61 ± 2.14)• Sex (M/F): treatment group 1 (22/52); treatment group 2 (20/50)• Uropathy: treatment group 1 (18); treatment group 2 (23)• Exclusion criteria: allergy to aminoglycosides, renal or hearing dysfunction, neuropathic bladder, uri-
nary diversion
Interventions Treatment group 1
• IM netilmicin: 5 mg/kg/d in 1 dose for 10 days
Treatment group 2
• IM netilmicin: 2 mg/kg/dose, 3 doses/d for 10 days
Outcomes • Persistent bacteriuria at 7 days and recurrent UTI by 30 days after end of therapy• Adverse effects
Notes • Definition of APN: UTI and fever > 38.5°C, ESR > 25, CRP > 20 mg/L• 144/150 enrolled were evaluated for efficacy and included. 6/144 (4%) excluded for inadequate fol-
low-up
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated that patients were randomly allocated
Vigano 1992 
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Allocation concealment
(selection bias)
Unclear risk Stated that patients were randomly allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding but primary outcome was laboratory based and unlikely to be in-
fluenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 6/150 (4%) excluded from analysis. This is unlikely to influence results
Selective reporting (re-
porting bias)
High risk No clinical outcomes reported
Other bias Unclear risk No information provided
Vigano 1992  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 1 January 1998 to 31 July 199• Duration of follow-up: 6 months• Power calculation: NS
Participants • Country: Thailand• Setting: Tertiary centre IP/OPD• Children aged 1 month to 15 years; fever, pyuria; positive urine culture, DMSA scan demonstrated cor-
tical defect• Urine collection: MSU, bag• Number: treatment group 1 (18); treatment group 2 (18)• Mean age ± SD (months): treatment group 1 (26.7 ± 31.6); treatment group 2 (14.8 ± 21.08)• Sex (M/F): treatment group 1 (9/9); treatment group 2 (10/8)• VUR: treatment group 1 (3); treatment group 2 (4)• Exclusion criteria: age < 1 month; previous UTI; known uropathy; allergic to study antibiotics; kidney
failure; chronic disease; antibiotics in previous 48 hours
Interventions Treatment group 1
• IV ceftriaxone: 75 mg/kg/d in single dose till fever resolved• Oral ceCibuten: 9 mg/kg/d (dose frequency NS)• Total duration 10 days
Treatment group 2
• IV ceftriaxone: 75 mg/kg/d in single dose for 10 days
Outcomes • Abnormal DMSA at 6 months• Recurrent UTI during 6 months• Persistent bacteriuria at end of treatment
Vilaichone 2001 
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Notes • Definition of APN: UTI and fever > 38°C, subnormal temperature in infants, acute defects on DMSA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomized by blocks of four"
Allocation concealment
(selection bias)
Unclear risk Only information provided is "prospective randomized trial"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding. Lack of blinding could influence clinical management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was DMSA scan results. "The site and number of lesions for
each kidney were independently reported by 2 experienced nuclear medicine
physicians"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients completed follow-up
Selective reporting (re-
porting bias)
High risk Incomplete reporting of adverse effects
Other bias Unclear risk No information provided
Vilaichone 2001  (Continued)
Amox/clav - amoxicillin/clavulanic acid; APN - acute pyelonephritis; CKD - chronic kidney disease; CRP - C reactive protein; CT - computer
tomography; DMSA - Tc99m-dimercaptosuccinic acid nuclear scan; ED - emergency department; ESR - erythrocyte sedimentation rate; IM -
intramuscular; IP - inpatient; IQR - interquartile range; MSU - midstream urine specimen; NS - not stated; OAE - otoacoustic emission; OPD -
outpatient department; SPA - suprapubic bladder aspiration; TMP/SMX - trimethoprim/sulphamethoxazole; US - ultrasound; UTI - urinary
tract infection; VUR - vesicoureteric reflux; WBC - white blood count
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adam 1982 RCT; lower UTI
Avner 1983 RCT; lower UTI
Belet 2004 RCT; prophylaxis study
Bose 1974 Quasi-RCT; cannot separate data on children with pyelonephritis from those with lower UTI
Clemente 1994 RCT; immunomodulating agents not antibiotics in APN
Cox 1985 Adult data
Dagan 1992 RCT; cannot separate data on children with APN from those with lower UTI
Ellerstein 1977 RCT; unclear as to whether patients with APN included
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Study Reason for exclusion
Elo 1975 RCT; cannot separate data on children with APN from those with lower UTI
Fine 1985 RCT; lower UTI
Francois 1995 RCT; cannot separate data on children with APN from those with lower UTI
Garin 2006 RCT; prophylaxis study
Ginsburg 1982 RCT; cannot separate data on children with APN from those with lower UTI
Godard 1980 Not RCT
Gok 2001 RCT; cannot separate data on children with APN from those with lower UTI
Goldberg 1977 RCT; cannot separate data on children with APN from those with lower UTI
Helin 1978 Not RCT
Howard 1971 Not RCT
Howard 1978 RCT; cannot separate data on children with APN from those with lower UTI
Huang 2011 RCT comparing effect of methylprednisolone vs placebo on kidney scarring with same antibiotic
regimen in each group
Iravani 1992 RCT; lower UTI
Ivanov 1999 RCT; does not compare antibiotic therapies
Kenda 1995 RCT; cannot separate data on children with APN from those with lower UTI
Kontiokari 2005 RCT; prophylaxis study
Kornberg 1994 RCT; lower UTI
Lake 1971 RCT; UTI but cannot separate data for febrile children from adult data
Lubitz 1984 RCT; cannot separate data on children with APN from those with lower UTI
Madrigal 1988 RCT; cannot separate data on children with APN from those with lower UTI
Moe 1977 RCT; cannot separate data on children with APN from those with lower UTI
Olbing 1970 RCT; prophylaxis study
Orekhova 2009 Study of non-antibiotic (immunological stimulating agent) as prophylaxis against UTI
Palcoux 1986 Not RCT
Petersen 1991 RCT; lower UTI
Piekkala 1985 Not RCT
Pitt 1982 RCT; cannot separate data on children with APN from those with lower UTI
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Study Reason for exclusion
Ray 1970 RCT; prophylaxis
Russo 1977 RCT; cannot separate data on children with APN from those with lower UTI
Sember 1985 RCT; cannot separate data on children with APN from those with lower UTI
Shapiro 1981 RCT; lower UTI
Thomas 1972 Not RCT
Vlatković 1972 Not RCT
Wallen 1983 RCT; lower UTI
Weber 1982 RCT; cannot separate data on children with APN from those with lower UTI
APN - acute pyelonephritis; RCT - randomised controlled trial; UTI - urinary tract infection
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Short-term antibiotic therapy for pyelonephritis in childhood (STUTI)
Methods Country: Italy, USA
Tertiary hospital ED
Participants Inclusion: children aged 1 month to 5 years with first episode of acute pyelonephritis
Exclusions: children with vomiting/sepsis or other condition where oral antibiotics could not be
given. Pyelonephritis with abscess. Allergy to ceCibuten. Antibiotic prophylaxis with antibiotic of
same class
Interventions Group1: oral ceCibuten 9 mg/kg once daily for 7 days
Group 2: oral ceCibuten 9 mg/kg once daily for 10 days
Outcomes 1. Rate of kidney parenchymal damage at 6 to 12 months post UTI
2. Relapses of UTI
3. Adverse effect of therapy
Starting date Start date: July 2006
Contact information Maria Lazzerini, IRCCS Burlo Garofolo
Notes Trial terminated because of patients' refusal of DMSA scans on follow-up
NCT00724256 
DMSA - Tc99m-dimercaptosuccinic acid nuclear scan; ED - emergency department; UTI - urinary tract infection
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Comparison 1.   Oral versus IV followed by oral (11 days) therapy
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Time to fever resolution 2 808 Mean Difference (IV, Random, 95% CI) 2.05 [-0.84, 4.94]
2 Fever on Day 3 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Number with persistent UTI
at 72 hours
2 542 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.07, 17.41]
4 Inflammatory markers at 72
hours
1   Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 WCC [×109/L] 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 ESR [mm/60 min] 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 CRP [mg/L] 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Recurrent UTI within 6
months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Total UTIs 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Symptomatic UTIs 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Persistent kidney damage
at 6-12 months
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 All included patients with
acute pyelonephritis
4 943 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.59, 1.12]
6.2 Patients with kidney
parenchymal damage on ini-
tial DMSA
4 681 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.61, 1.03]
7 Proportion of kidney
parenchyma with damage at
6 months
1   Mean Difference (IV, Random, 95% CI) Subtotals only
8 Kidney damage at 6 months
(post hoc subgroup analysis)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Persistent damage in chil-
dren with VUR
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Persistent damage in chil-
dren without VUR
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Persistent kidney damage
with VUR grades 1-2
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Persistent damage with
VUR grades 3-5
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1.   Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 1 Time to fever resolution.
Study or subgroup Oral therapy IV then oral therapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hoberman 1999 153 24.7 (23.2) 153 23.9 (23.3) 30.77% 0.8[-4.41,6.01]
Montini 2007 244 36.9 (19.7) 258 34.3 (20) 69.23% 2.6[-0.87,6.07]
   
Total *** 397   411   100% 2.05[-0.84,4.94]
Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%  
Test for overall effect: Z=1.39(P=0.17)  
Oral therapy 105-10 -5 0 IV then oral therapy
 
 
Analysis 1.2.   Comparison 1 Oral versus IV followed by oral (11 days) therapy, Outcome 2 Fever on Day 3.
Study or subgroup Oral therapy IV then oral therapy Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Neuhaus 2008 7/80 8/72 0.79[0.3,2.06]
Oral therapy 100.1 50.2 20.5 1 IV then oral therapy
 
 
Analysis 1.3.   Comparison 1 Oral versus IV followed by oral (11
days) therapy, Outcome 3 Number with persistent UTI at 72 hours.
Study or subgroup Oral therapy IV then oral
therapy
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Montini 2007 1/186 1/204 100% 1.1[0.07,17.41]
Neuhaus 2008 0/80 0/72   Not estimable
   
Total (95% CI) 266 276 100% 1.1[0.07,17.41]
Total events: 1 (Oral therapy), 1 (IV then oral therapy)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.07(P=0.95)  
Oral therapy 200.05 50.2 1 IV then oral therapy
 
 
Analysis 1.4.   Comparison 1 Oral versus IV followed by oral (11
days) therapy, Outcome 4 Inflammatory markers at 72 hours.
Study or subgroup Oral therapy IV then oral therapy Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.4.1 WCC [×109/L]  
Montini 2007 230 9.8 (3.5) 243 9.5 (3.1) 0.3[-0.3,0.9]
   
1.4.2 ESR [mm/60 min]  
Montini 2007 170 50.8 (32) 168 52.6 (27.9) -1.8[-8.2,4.6]
   
Oral therapy 105-10 -5 0 IV then oral therapy
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Study or subgroup Oral therapy IV then oral therapy Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.4.3 CRP [mg/L]  
Montini 2007 235 9.3 (20.9) 251 8.2 (15.4) 1.1[-2.18,4.38]
Oral therapy 105-10 -5 0 IV then oral therapy
 
 
Analysis 1.5.   Comparison 1 Oral versus IV followed by oral
(11 days) therapy, Outcome 5 Recurrent UTI within 6 months.
Study or subgroup Oral therapy IV then oral therapy Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.5.1 Total UTIs  
Hoberman 1999 8/140 13/147 0.65[0.28,1.51]
   
1.5.2 Symptomatic UTIs  
Hoberman 1999 7/140 11/147 0.67[0.27,1.67]
Oral therapy 50.2 20.5 1 IV then oral therapy
 
 
Analysis 1.6.   Comparison 1 Oral versus IV followed by oral (11 days)
therapy, Outcome 6 Persistent kidney damage at 6-12 months.
Study or subgroup Oral therapy IV then oral
therapy
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 All included patients with acute pyelonephritis  
Hoberman 1999 15/132 11/140 14.29% 1.45[0.69,3.03]
Montini 2007 27/197 36/203 27.22% 0.77[0.49,1.22]
Neuhaus 2008 21/80 33/72 28.16% 0.57[0.37,0.89]
Bocquet 2012 25/61 26/58 30.33% 0.91[0.6,1.38]
Subtotal (95% CI) 470 473 100% 0.82[0.59,1.12]
Total events: 88 (Oral therapy), 106 (IV then oral therapy)  
Heterogeneity: Tau2=0.04; Chi2=5.05, df=3(P=0.17); I2=40.61%  
Test for overall effect: Z=1.24(P=0.22)  
   
1.6.2 Patients with kidney parenchymal damage on initial DMSA  
Hoberman 1999 15/100 11/87 12.02% 1.19[0.58,2.44]
Neuhaus 2008 21/80 33/72 27.57% 0.57[0.37,0.89]
Montini 2007 27/109 36/114 29.69% 0.78[0.51,1.2]
Bocquet 2012 25/61 26/58 30.72% 0.91[0.6,1.38]
Subtotal (95% CI) 350 331 100% 0.79[0.61,1.03]
Total events: 88 (Oral therapy), 106 (IV then oral therapy)  
Heterogeneity: Tau2=0.01; Chi2=3.7, df=3(P=0.3); I2=18.93%  
Test for overall effect: Z=1.73(P=0.08)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.88), I2=0%  
Oral therapy 50.2 20.5 1 IV then oral therapy
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Analysis 1.7.   Comparison 1 Oral versus IV followed by oral (11 days) therapy,
Outcome 7 Proportion of kidney parenchyma with damage at 6 months.
Study or subgroup Oral therapy IV then oral therapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hoberman 1999 132 7.9 (2.7) 140 8.6 (5.6) 0% -0.7[-1.74,0.34]
Oral therapy 21-2 -1 0 IV then oral therapy
 
 
Analysis 1.8.   Comparison 1 Oral versus IV followed by oral (11 days) therapy,
Outcome 8 Kidney damage at 6 months (post hoc subgroup analysis).
Study or subgroup Oral therapy IV then oral therapy Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.8.1 Persistent damage in children with VUR  
Hoberman 1999 15/57 7/50 1.88[0.83,4.24]
   
1.8.2 Persistent damage in children without VUR  
Hoberman 1999 4/75 6/90 0.8[0.23,2.73]
   
1.8.3 Persistent kidney damage with VUR grades 1-2  
Hoberman 1999 3/33 4/28 0.64[0.16,2.61]
   
1.8.4 Persistent damage with VUR grades 3-5  
Hoberman 1999 8/24 1/22 7.33[1,54.01]
Oral therapy 1000.01 100.1 1 IV then oral therapy
 
 
Comparison 2.   Short duration (3-4 days) versus long duration (7-14 days) IV therapy
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria after
treatment
4 305 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.24, 2.55]
2 Recurrent UTI within 6 months 5 993 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.58, 1.62]
3 Persistent kidney damage at
3-6 months
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 All included patients with
acute pyelonephritis
4 726 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.80, 1.29]
3.2 Patients with renal parenchy-
mal damage on initial DMSA scan
3 315 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.84, 1.45]
4 Persistent kidney damage at
3-6 months (post hoc subgroup
analysis)
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 VUR present 2 81 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.69, 1.43]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.2 No VUR 2 173 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.81, 1.76]
4.3 Age less than 1 year 1 91 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.71, 3.01]
4.4 Age 1 year or over 1 129 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.59, 1.34]
4.5 Delay in treatment less than 7
days in individual kidneys
1 53 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.59, 3.92]
4.6 Delay in treatment of 7 days
or more in individual kidneys
1 12 Risk Ratio (M-H, Random, 95% CI) 2.10 [0.92, 4.77]
5 Adverse effects 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Gastrointestinal effects 2 175 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.55, 3.05]
 
 
Analysis 2.1.   Comparison 2 Short duration (3-4 days) versus long duration
(7-14 days) IV therapy, Outcome 1 Persistent bacteriuria aFer treatment.
Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Levtchenko 2001 0/44 0/43   Not estimable
Vilaichone 2001 0/18 0/18   Not estimable
Francois 1997 1/63 0/65 13.88% 3.09[0.13,74.55]
Noorbakhsh 2004 3/24 6/30 86.12% 0.63[0.17,2.24]
   
Total (95% CI) 149 156 100% 0.78[0.24,2.55]
Total events: 4 (Short duration), 6 (Long duration)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
Short duration 1000.01 100.1 1 Long duration
 
 
Analysis 2.2.   Comparison 2 Short duration (3-4 days) versus long duration
(7-14 days) IV therapy, Outcome 2 Recurrent UTI within 6 months.
Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Francois 1997 0/49 2/53 2.88% 0.22[0.01,4.39]
Vilaichone 2001 2/18 1/18 4.89% 2[0.2,20.15]
Levtchenko 2001 2/44 3/43 8.62% 0.65[0.11,3.71]
Benador 2001 9/110 6/110 26.16% 1.5[0.55,4.07]
Bouissou 2008 15/277 17/271 57.45% 0.86[0.44,1.69]
   
Total (95% CI) 498 495 100% 0.97[0.58,1.62]
Total events: 28 (Short duration), 29 (Long duration)  
Heterogeneity: Tau2=0; Chi2=2.39, df=4(P=0.67); I2=0%  
Short duration 1000.01 100.1 1 Long duration
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Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.1(P=0.92)  
Short duration 1000.01 100.1 1 Long duration
 
 
Analysis 2.3.   Comparison 2 Short duration (3-4 days) versus long duration
(7-14 days) IV therapy, Outcome 3 Persistent kidney damage at 3-6 months.
Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 All included patients with acute pyelonephritis  
Levtchenko 2001 11/44 8/43 8.75% 1.34[0.6,3.01]
Vilaichone 2001 12/18 11/18 23.56% 1.09[0.67,1.79]
Bouissou 2008 26/205 31/178 24.7% 0.73[0.45,1.18]
Benador 2001 40/110 36/110 42.99% 1.11[0.77,1.6]
Subtotal (95% CI) 377 349 100% 1.01[0.8,1.29]
Total events: 89 (Short duration), 86 (Long duration)  
Heterogeneity: Tau2=0; Chi2=2.66, df=3(P=0.45); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
2.3.2 Patients with renal parenchymal damage on initial DMSA scan  
Levtchenko 2001 11/33 8/26 13.19% 1.08[0.51,2.3]
Vilaichone 2001 12/18 11/18 30.73% 1.09[0.67,1.79]
Benador 2001 40/110 36/110 56.08% 1.11[0.77,1.6]
Subtotal (95% CI) 161 154 100% 1.1[0.84,1.45]
Total events: 63 (Short duration), 55 (Long duration)  
Heterogeneity: Tau2=0; Chi2=0.01, df=2(P=1); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Short duration 50.2 20.5 1 Long duration
 
 
Analysis 2.4.   Comparison 2 Short duration (3-4 days) versus long duration (7-14 days) IV
therapy, Outcome 4 Persistent kidney damage at 3-6 months (post hoc subgroup analysis).
Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 VUR present  
Benador 2001 14/36 15/38 40.82% 0.99[0.56,1.74]
Vilaichone 2001 3/3 4/4 59.18% 1[0.62,1.6]
Subtotal (95% CI) 39 42 100% 0.99[0.69,1.43]
Total events: 17 (Short duration), 19 (Long duration)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%  
Test for overall effect: Z=0.03(P=0.97)  
   
2.4.2 No VUR  
Benador 2001 25/72 21/72 65.94% 1.19[0.74,1.92]
Vilaichone 2001 9/15 7/14 34.06% 1.2[0.62,2.34]
Subtotal (95% CI) 87 86 100% 1.19[0.81,1.76]
Total events: 34 (Short duration), 28 (Long duration)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Short duration 50.2 20.5 1 Long duration
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Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.89(P=0.37)  
   
2.4.3 Age less than 1 year  
Benador 2001 11/37 11/54 100% 1.46[0.71,3.01]
Subtotal (95% CI) 37 54 100% 1.46[0.71,3.01]
Total events: 11 (Short duration), 11 (Long duration)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.02(P=0.31)  
   
2.4.4 Age 1 year or over  
Benador 2001 29/73 25/56 100% 0.89[0.59,1.34]
Subtotal (95% CI) 73 56 100% 0.89[0.59,1.34]
Total events: 29 (Short duration), 25 (Long duration)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.56(P=0.57)  
   
2.4.5 Delay in treatment less than 7 days in individual kidneys  
Levtchenko 2001 7/23 6/30 100% 1.52[0.59,3.92]
Subtotal (95% CI) 23 30 100% 1.52[0.59,3.92]
Total events: 7 (Short duration), 6 (Long duration)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
   
2.4.6 Delay in treatment of 7 days or more in individual kidneys  
Levtchenko 2001 5/5 3/7 100% 2.1[0.92,4.77]
Subtotal (95% CI) 5 7 100% 2.1[0.92,4.77]
Total events: 5 (Short duration), 3 (Long duration)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.76(P=0.08)  
Short duration 50.2 20.5 1 Long duration
 
 
Analysis 2.5.   Comparison 2 Short duration (3-4 days) versus
long duration (7-14 days) IV therapy, Outcome 5 Adverse e4ects.
Study or subgroup Short duration Long duration Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Gastrointestinal effects  
Vilaichone 2001 1/18 0/18 7.49% 3[0.13,69.09]
Francois 1997 9/67 8/72 92.51% 1.21[0.5,2.95]
Subtotal (95% CI) 85 90 100% 1.29[0.55,3.05]
Total events: 10 (Short duration), 8 (Long duration)  
Heterogeneity: Tau2=0; Chi2=0.3, df=1(P=0.58); I2=0%  
Test for overall effect: Z=0.59(P=0.56)  
Short duration 1000.01 100.1 1 Long duration
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Comparison 3.   Single dose parenteral therapy and oral therapy versus oral therapy alone
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria at 48 hours 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Treatment failure after 48 hours of
therapy
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Recurrent UTI within 1 month 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Total adverse events 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Gastrointestinal adverse events 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Single dose parenteral therapy and oral therapy
versus oral therapy alone, Outcome 1 Persistent bacteriuria at 48 hours.
Study or subgroup Ceftriaxone/TMP+SMX TMP+SMX Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Baker 2001 3/34 4/35 0.77[0.19,3.2]
Ceftriaxone/TMP+SMX 100.1 50.2 20.5 1 TMP+SMX
 
 
Analysis 3.2.   Comparison 3 Single dose parenteral therapy and oral therapy
versus oral therapy alone, Outcome 2 Treatment failure aFer 48 hours of therapy.
Study or subgroup Ceftriaxone/TMP+SMX TMP+SMX Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Baker 2001 4/34 5/35 0.82[0.24,2.81]
Ceftriaxone/TMP+SMX 50.2 20.5 1 TMP+SMX
 
 
Analysis 3.3.   Comparison 3 Single dose parenteral therapy and oral therapy
versus oral therapy alone, Outcome 3 Recurrent UTI within 1 month.
Study or subgroup Ceftriaxone/TMP+SMX TMP+SMX Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Baker 2001 0/34 0/35 Not estimable
Ceftriaxone/TMP+SMX 100.1 50.2 20.5 1 TMP+SMX
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Analysis 3.4.   Comparison 3 Single dose parenteral therapy and
oral therapy versus oral therapy alone, Outcome 4 Adverse events.
Study or subgroup Ceftriaxone/TMP+SMX TMP+SMX Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.4.1 Total adverse events  
Baker 2001 4/34 3/35 1.37[0.33,5.68]
   
3.4.2 Gastrointestinal adverse events  
Baker 2001 3/34 3/35 1.03[0.22,4.75]
Ceftiaxone/TMP+SMX 100.1 50.2 20.5 1 TMP+SMX
 
 
Comparison 4.   Di4erent dosing regimens of aminoglycosides (daily versus 8 hourly)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria after 1-3 days
of treatment
3 435 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.15, 7.27]
2 Persistent symptoms at end of 3
days of IV therapy
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Persistent bacteriuria at 1 week af-
ter treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Reinfection at 1 month after com-
pleting treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Hearing impairment following
treatment
3 271 Risk Ratio (M-H, Random, 95% CI) 2.83 [0.33, 24.56]
6 Increase in serum creatinine during
treatment
3 419 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.20, 2.82]
7 Time to resolution of fever 1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 Kidney parenchymal damage at 3
months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 4.1.   Comparison 4 Di4erent dosing regimens of aminoglycosides (daily
versus 8 hourly), Outcome 1 Persistent bacteriuria aFer 1-3 days of treatment.
Study or subgroup Daily treatment 8 hourly
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Vigano 1992 0/74 0/70   Not estimable
Carapetis 2001 0/60 0/59   Not estimable
Chong 2003 2/84 2/88 100% 1.05[0.15,7.27]
   
Daily treatment 100.1 50.2 20.5 1 8 hourly treatment
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Study or subgroup Daily treatment 8 hourly
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 218 217 100% 1.05[0.15,7.27]
Total events: 2 (Daily treatment), 2 (8 hourly treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
Daily treatment 100.1 50.2 20.5 1 8 hourly treatment
 
 
Analysis 4.2.   Comparison 4 Di4erent dosing regimens of aminoglycosides (daily
versus 8 hourly), Outcome 2 Persistent symptoms at end of 3 days of IV therapy.
Study or subgroup Daily treatment 8 hourly treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Carapetis 2001 4/90 2/89 1.98[0.37,10.53]
Daily treatment 200.05 50.2 1 8 hourly treatment
 
 
Analysis 4.3.   Comparison 4 Di4erent dosing regimens of aminoglycosides (daily
versus 8 hourly), Outcome 3 Persistent bacteriuria at 1 week aFer treatment.
Study or subgroup Daily treatment 8 hourly treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Vigano 1992 1/74 0/70 2.84[0.12,68.57]
Daily treatment 1000.01 100.1 1 8 hourly treatment
 
 
Analysis 4.4.   Comparison 4 Di4erent dosing regimens of aminoglycosides (daily
versus 8 hourly), Outcome 4 Reinfection at 1 month aFer completing treatment.
Study or subgroup Daily treatment 8 hourly treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Vigano 1992 5/74 4/70 1.18[0.33,4.23]
Daily treatment 50.2 20.5 1 8 hourly treatment
 
 
Analysis 4.5.   Comparison 4 Di4erent dosing regimens of aminoglycosides
(daily versus 8 hourly), Outcome 5 Hearing impairment following treatment.
Study or subgroup Daily treatment 8 hourly
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chong 2003 0/79 0/88   Not estimable
Carapetis 2001 1/39 0/33 46.55% 2.55[0.11,60.57]
Vigano 1992 2/20 0/12 53.45% 3.1[0.16,59.52]
   
Total (95% CI) 138 133 100% 2.83[0.33,24.56]
Daily treatment 1000.01 100.1 1 8 hourly treatment
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Study or subgroup Daily treatment 8 hourly
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 3 (Daily treatment), 0 (8 hourly treatment)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Daily treatment 1000.01 100.1 1 8 hourly treatment
 
 
Analysis 4.6.   Comparison 4 Di4erent dosing regimens of aminoglycosides (daily
versus 8 hourly), Outcome 6 Increase in serum creatinine during treatment.
Study or subgroup Daily treatment 8 hourly
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Carapetis 2001 1/64 1/52 22.97% 0.81[0.05,12.68]
Vigano 1992 2/74 2/70 46.43% 0.95[0.14,6.53]
Chong 2003 1/79 2/80 30.6% 0.51[0.05,5.47]
   
Total (95% CI) 217 202 100% 0.75[0.2,2.82]
Total events: 4 (Daily treatment), 5 (8 hourly treatment)  
Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
Daily treatment 500.02 100.1 1 8 hourly treatment
 
 
Analysis 4.7.   Comparison 4 Di4erent dosing regimens of aminoglycosides
(daily versus 8 hourly), Outcome 7 Time to resolution of fever.
Study or subgroup Daily treatment 8 hourly treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Chong 2003 84 47.4 (34.6) 88 45 (34.3) 2.4[-7.9,12.7]
Daily treatment 2010-20 -10 0 8 hourly treatment
 
 
Analysis 4.8.   Comparison 4 Di4erent dosing regimens of aminoglycosides
(daily versus 8 hourly), Outcome 8 Kidney parenchymal damage at 3 months.
Study or subgroup Daily treatment 8 hourly treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Chong 2003 18/75 23/71 0.74[0.44,1.25]
Daily treatment 50.2 20.5 1 8 hourly treatment
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Comparison 5.   Third generation cephalosporin versus other antibiotic
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria 3 439 Risk Ratio (M-H, Random, 95% CI) 2.41 [0.98, 5.93]
2 Recurrent UTI after end of ther-
apy
4 491 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.32, 4.74]
3 Persistent symptoms after end
of treatment
3 471 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.13, 0.62]
4 Number with fever for more
than 48 hours
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Recurrent bacteriuria at 4-6
weeks
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Recurrent symptomatic UTI at
4-6 weeks
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Gastrointestinal adverse events 4 591 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.34, 2.58]
8 Number discontinuing treat-
ment for adverse effect
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 5.1.   Comparison 5 Third generation cephalosporin
versus other antibiotic, Outcome 1 Persistent bacteriuria.
Study or subgroup Cephalosporin Other an-
tibiotic
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Toporovski 1992 0/26 0/11   Not estimable
Fischbach 1989 2/9 0/10 9.57% 5.5[0.3,101.28]
Marild 2009 22/255 5/128 90.43% 2.21[0.86,5.7]
   
Total (95% CI) 290 149 100% 2.41[0.98,5.93]
Total events: 24 (Cephalosporin), 5 (Other antibiotic)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=1.91(P=0.06)  
Cephalosporin 2000.005 100.1 1 Other antibiotic
 
 
Analysis 5.2.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 2 Recurrent UTI aFer end of therapy.
Study or subgroup Cephalosporin Other an-
tibiotic
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Toporovski 1992 0/26 0/11   Not estimable
Cephalosporin 500.02 100.1 1 Other antibiotic
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Study or subgroup Cephalosporin Other an-
tibiotic
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fischbach 1989 0/10 0/10   Not estimable
Banfi 1993 1/36 1/15 24.88% 0.42[0.03,6.23]
Marild 2009 7/255 2/128 75.12% 1.76[0.37,8.34]
   
Total (95% CI) 327 164 100% 1.23[0.32,4.74]
Total events: 8 (Cephalosporin), 3 (Other antibiotic)  
Heterogeneity: Tau2=0; Chi2=0.82, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.3(P=0.77)  
Cephalosporin 500.02 100.1 1 Other antibiotic
 
 
Analysis 5.3.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 3 Persistent symptoms aFer end of treatment.
Study or subgroup Cephalosporin Other an-
tibiotic
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Toporovski 1992 0/26 0/11   Not estimable
Banfi 1993 1/36 0/15 6.38% 1.3[0.06,30.17]
Marild 2009 8/255 16/128 93.62% 0.25[0.11,0.57]
   
Total (95% CI) 317 154 100% 0.28[0.13,0.62]
Total events: 9 (Cephalosporin), 16 (Other antibiotic)  
Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%  
Test for overall effect: Z=3.15(P=0)  
Cephalosporin 500.02 100.1 1 Other antibiotic
 
 
Analysis 5.4.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 4 Number with fever for more than 48 hours.
Study or subgroup Cephalosporin Other antibiotic Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Fischbach 1989 2/10 0/10 5[0.27,92.62]
Cephalosporin 1000.01 100.1 1 Other antibiotic
 
 
Analysis 5.5.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 5 Recurrent bacteriuria at 4-6 weeks.
Study or subgroup Cephalosporin Other antibiotic Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Banfi 1993 2/20 0/8 2.14[0.11,40.3]
Cephalosporin 500.02 100.1 1 Other antibiotic
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Analysis 5.6.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 6 Recurrent symptomatic UTI at 4-6 weeks.
Study or subgroup Cephalosporin Other antibiotic Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Banfi 1993 0/20 0/15 Not estimable
Cephalosporin 100.1 50.2 20.5 1 Other antibiotic
 
 
Analysis 5.7.   Comparison 5 Third generation cephalosporin versus
other antibiotic, Outcome 7 Gastrointestinal adverse events.
Study or subgroup Cephalosporin Other an-
tibiotic
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Toporovski 1992 3/26 0/11 12.54% 3.11[0.17,55.65]
Fischbach 1989 0/10 3/10 12.9% 0.14[0.01,2.45]
Banfi 1993 1/52 1/21 14.04% 0.4[0.03,6.16]
Marild 2009 8/309 3/152 60.52% 1.31[0.35,4.87]
   
Total (95% CI) 397 194 100% 0.93[0.34,2.58]
Total events: 12 (Cephalosporin), 7 (Other antibiotic)  
Heterogeneity: Tau2=0; Chi2=2.98, df=3(P=0.4); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Cephalosporin 1000.01 100.1 1 Other antibiotic
 
 
Analysis 5.8.   Comparison 5 Third generation cephalosporin versus other
antibiotic, Outcome 8 Number discontinuing treatment for adverse e4ect.
Study or subgroup Cephalosporin Other antibiotic Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Marild 2009 4/309 4/152 0.49[0.12,1.94]
Cephalosporin 100.1 50.2 20.5 1 Other antibiotic
 
 
Comparison 6.   Cefepime versus ceFazidime
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistence or recurrence
of initial pathogen
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 At end of IV therapy 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 At the end of IV and oral
therapy
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 At 5-9 days after treat-
ment
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Antibiotics for acute pyelonephritis in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
77
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 At 4-6 weeks after treat-
ment
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Infection with new
pathogen at 4-6 weeks
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Unsatisfactory clinical re-
sponse
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 At end of IV therapy 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 At end of IV and oral ther-
apy
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 At 5-9 days after treat-
ment
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 At 4-6 weeks after treat-
ment
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Adverse effects 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Total adverse events 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Drug-related adverse ef-
fects
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Gastrointestinal adverse
effects
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Cutaneous adverse ef-
fects
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Discontinuation due to
drug related adverse effects
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 6.1.   Comparison 6 Cefepime versus ceFazidime, Outcome 1 Persistence or recurrence of initial pathogen.
Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.1.1 At end of IV therapy  
Schaad 1998 1/111 0/113 3.05[0.13,74.16]
   
6.1.2 At the end of IV and oral therapy  
Schaad 1998 0/96 4/102 0.12[0.01,2.16]
   
6.1.3 At 5-9 days after treatment  
Schaad 1998 5/96 2/91 2.37[0.47,11.91]
   
Cefepime 2000.005 100.1 1 Ceftazidime
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Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.1.4 At 4-6 weeks after treatment  
Schaad 1998 1/91 8/97 0.13[0.02,1.04]
Cefepime 2000.005 100.1 1 Ceftazidime
 
 
Analysis 6.2.   Comparison 6 Cefepime versus ceFazidime, Outcome 2 Infection with new pathogen at 4-6 weeks.
Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Schaad 1998 8/115 7/120 1.19[0.45,3.18]
Cefepime 50.2 20.5 1 Ceftazidime
 
 
Analysis 6.3.   Comparison 6 Cefepime versus ceFazidime, Outcome 3 Unsatisfactory clinical response.
Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.3.1 At end of IV therapy  
Schaad 1998 2/115 3/118 0.68[0.12,4.02]
   
6.3.2 At end of IV and oral therapy  
Schaad 1998 2/100 0/102 5.1[0.25,104.9]
   
6.3.3 At 5-9 days after treatment  
Schaad 1998 2/99 0/100 5.05[0.25,103.87]
   
6.3.4 At 4-6 weeks after treatment  
Schaad 1998 2/95 8/105 0.28[0.06,1.27]
Cefepime 2000.005 100.1 1 Ceftazidime
 
 
Analysis 6.4.   Comparison 6 Cefepime versus ceFazidime, Outcome 4 Adverse e4ects.
Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.4.1 Total adverse events  
Schaad 1998 41/149 37/150 1.12[0.76,1.63]
   
6.4.2 Drug-related adverse effects  
Schaad 1998 14/149 10/150 1.41[0.65,3.07]
   
6.4.3 Gastrointestinal adverse effects  
Schaad 1998 10/149 9/150 1.12[0.47,2.67]
   
6.4.4 Cutaneous adverse effects  
Schaad 1998 3/149 2/150 1.51[0.26,8.91]
   
Cefepime 500.02 100.1 1 Ceftazidime
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Study or subgroup Cefepime Ceftazidine Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.4.5 Discontinuation due to drug related adverse effects  
Schaad 1998 4/149 1/150 4.03[0.46,35.61]
Cefepime 500.02 100.1 1 Ceftazidime
 
 
Comparison 7.   CeFriaxone versus cefotaxime
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria at 48 hours 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
2 Bacteriuria 10 days after end of treatment 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
2.1 All patients 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
2.2 Normal renal tract imaging (post hoc analy-
sis)
1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
2.3 Abnormal renal tract imaging (post hoc
analysis)
1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
3 UTI at 1 month after therapy 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
3.1 All patients 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
3.2 Normal renal tract imaging 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
3.3 Abnormal renal tract imaging 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
4 Adverse events 1   Risk Ratio (M-H, Random,
95% CI)
Totals not selected
4.1 All adverse events 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
4.2 Skin eruptions 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
4.3 Gastrointestinal adverse events 1   Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
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Analysis 7.1.   Comparison 7 CeFriaxone versus cefotaxime, Outcome 1 Persistent bacteriuria at 48 hours.
Study or subgroup Ceftriaxone Cefotaxime Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Bakkaloglu 1996 0/50 0/50 Not estimable
Ceftriaxone 1000.01 100.1 1 Cefotaxime
 
 
Analysis 7.2.   Comparison 7 CeFriaxone versus cefotaxime, Outcome 2 Bacteriuria 10 days aFer end of treatment.
Study or subgroup Ceftriaxone Cefotaxime Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
7.2.1 All patients  
Bakkaloglu 1996 8/42 9/41 0.87[0.37,2.03]
   
7.2.2 Normal renal tract imaging (post hoc analysis)  
Bakkaloglu 1996 5/26 4/29 1.39[0.42,4.65]
   
7.2.3 Abnormal renal tract imaging (post hoc analysis)  
Bakkaloglu 1996 3/24 5/21 0.53[0.14,1.94]
Ceftriaxone 100.1 50.2 20.5 1 Cefotaxime
 
 
Analysis 7.3.   Comparison 7 CeFriaxone versus cefotaxime, Outcome 3 UTI at 1 month aFer therapy.
Study or subgroup Ceftriaxone Cefotaxime Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
7.3.1 All patients  
Bakkaloglu 1996 8/42 11/39 0.68[0.3,1.5]
   
7.3.2 Normal renal tract imaging  
Bakkaloglu 1996 4/26 5/29 0.89[0.27,2.97]
   
7.3.3 Abnormal renal tract imaging  
Bakkaloglu 1996 4/24 6/21 0.58[0.19,1.79]
Ceftriaxone 100.1 50.2 20.5 1 Cefotaxime
 
 
Analysis 7.4.   Comparison 7 CeFriaxone versus cefotaxime, Outcome 4 Adverse events.
Study or subgroup Ceftriaxone Cefotaxime Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
7.4.1 All adverse events  
Bakkaloglu 1996 2/50 3/50 0.67[0.12,3.82]
   
7.4.2 Skin eruptions  
Bakkaloglu 1996 1/50 3/50 0.33[0.04,3.1]
   
7.4.3 Gastrointestinal adverse events  
Bakkaloglu 1996 1/50 0/50 3[0.13,71.92]
Ceftriaxone 1000.01 100.1 1 Cefotaxime
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Comparison 8.   Isepamicin versus amikacin
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 After 2-3 days of therapy 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 At 7 days after completing
therapy
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 At 30 days after completing
therapy
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 8.1.   Comparison 8 Isepamicin versus amikacin, Outcome 1 Persistent bacteriuria.
Study or subgroup Isepamicin Amikacin Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
8.1.1 After 2-3 days of therapy  
Kafetzis 2000 0/10 0/6 Not estimable
   
8.1.2 At 7 days after completing therapy  
Kafetzis 2000 0/10 0/6 Not estimable
   
8.1.3 At 30 days after completing therapy  
Kafetzis 2000 0/10 0/6 Not estimable
Isepamicin 1000.01 100.1 1 Amikacin
 
 
Comparison 9.   10 days versus 42 days of oral sulfafurazole
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrent UTI within 1 month after ceasing
therapy
1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
2 Recurrent UTI at 1-12 months after complet-
ing therapy
1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
 
 
Antibiotics for acute pyelonephritis in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
82
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 9.1.   Comparison 9 10 days versus 42 days of oral sulfafurazole,
Outcome 1 Recurrent UTI within 1 month aFer ceasing therapy.
Study or subgroup 10 days 42 days Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Pylkkänen 1981 17/73 1/76 17.7[2.42,129.61]
10 days 2000.005 100.1 1 42 days
 
 
Analysis 9.2.   Comparison 9 10 days versus 42 days of oral sulfafurazole,
Outcome 2 Recurrent UTI at 1-12 months aFer completing therapy.
Study or subgroup 10 days 42 days Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Pylkkänen 1981 10/73 12/76 0.87[0.4,1.88]
10 days 50.2 20.5 1 42 days
 
 
Comparison 10.   Single dose of parenteral antibiotic versus 7-10 days oral therapy
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistent bacteriuria 1-2 days after treat-
ment
2 35 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.18, 16.30]
2 UTI relapse or reinfection within 6 weeks 2 35 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.03, 1.97]
 
 
Analysis 10.1.   Comparison 10 Single dose of parenteral antibiotic versus 7-10
days oral therapy, Outcome 1 Persistent bacteriuria 1-2 days aFer treatment.
Study or subgroup Single dose 7-10 days Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Repetto 1984 0/4 1/7 47.96% 0.53[0.03,10.7]
Grimwood 1988 3/14 0/10 52.04% 5.13[0.29,89.57]
   
Total (95% CI) 18 17 100% 1.73[0.18,16.3]
Total events: 3 (Single dose), 1 (7-10 days)  
Heterogeneity: Tau2=0.39; Chi2=1.17, df=1(P=0.28); I2=14.71%  
Test for overall effect: Z=0.48(P=0.63)  
Single dose 1000.01 100.1 1 7-10 days
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Analysis 10.2.   Comparison 10 Single dose of parenteral antibiotic versus
7-10 days oral therapy, Outcome 2 UTI relapse or reinfection within 6 weeks.
Study or subgroup Single dose 7-10 days Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Repetto 1984 0/4 0/7   Not estimable
Grimwood 1988 1/14 3/10 100% 0.24[0.03,1.97]
   
Total (95% CI) 18 17 100% 0.24[0.03,1.97]
Total events: 1 (Single dose), 3 (7-10 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
Single dose 500.02 100.1 1 7-10 days
 
 
Comparison 11.   3 weeks versus 2 weeks
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistence/recurrence of bacteri-
uria
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Recurrence of clinical UTI 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 11.1.   Comparison 11 3 weeks versus 2 weeks, Outcome 1 Persistence/recurrence of bacteriuria.
Study or subgroup 3 weeks 2 weeks Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Cheng 2006 0/39 7/41 0.07[0,1.19]
3 weeks 5000.002 100.1 1 2 weeks
 
 
Analysis 11.2.   Comparison 11 3 weeks versus 2 weeks, Outcome 2 Recurrence of clinical UTI.
Study or subgroup 3 weeks 2 weeks Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Cheng 2006 0/39 2/41 0.21[0.01,4.24]
3 weeks 1000.01 100.1 1 2 weeks
 
 
Comparison 12.   Suppositories versus oral ampicillin
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Persistence of clinical symptoms 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Persistence of bacteriuria 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 12.1.   Comparison 12 Suppositories versus oral ampicillin, Outcome 1 Persistence of clinical symptoms.
Study or subgroup Suppositories Oral Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Fujii 1987 16/54 17/51 0.89[0.51,1.56]
Suppositories 20.5 1.50.7 1 Oral
 
 
Analysis 12.2.   Comparison 12 Suppositories versus oral ampicillin, Outcome 2 Persistence of bacteriuria.
Study or subgroup Suppositories Oral Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Fujii 1987 18/54 19/51 0.89[0.53,1.5]
Suppositories 20.5 1.50.7 1 Oral
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Reported outcomesStudy/ comparisons
  Persistent
bacteriuria
at 48 to 72
hours
Bacteriuria
at the end or
≥ 5 days of
treatment
UTI at fol-
low-up
Resolution
of clinical
symptoms
Sympto-
matic re-
currence of
UTI
Parenchy-
mal renal
damage on
DSMA scan
Adverse ef-
fects
Oral therapy versus sequential short duration IV therapy and oral therapy
Bocquet 2012       •   • •
Hoberman 1999     • •   •  
Montini 2007 •     •   • •
Neuhaus 2008           • •
Sequential short duration (3 to 4 days) IV therapy and oral therapy versus long duration (7to 14 days) IV therapy
Benador 2001     •     •  
Bouissou 2008           •  
Francois 1997   • •       •
Levtchenko 2001   • •     •  
Noorbakhsh 2004   •          
Vilaichone 2001   • •     • •
Single dose parenteral therapy and oral therapy versus oral therapy alone
Baker 2001 •   • •     •
Different dosing regimens of aminoglycoside therapy
Carapetis 2001 •     •     •
Chong 2003 •         • •
Vigano 1992   • •       •
Table 1.   Reported outcomes of included studies  (Continued)
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Third generation cephalosporins versus other antibiotics
Banfi 1993   • • • •   •
Fischbach 1989 •   • •     •
Marild 2009   •   •     •
Toporovski 1992   • •       •
Third generation cephalosporins versus fourth generation cephalosporins
Schaad 1998 • • • •     •
Ceftriaxone versus cefotaxime
Bakkaloglu 1996 • • •       •
Aminoglycosides versus aminoglycosides
Kafetzis 2000   • •       •
Different durations of the same oral antibiotic
Pylkkänen 1981     •        
Single dose parenteral therapy versus oral therapy alone
Grimwood 1988   • •        
Repetto 1984   • •        
Different durations of different antibiotics
Cheng 2006   •     •    
Different routes of antibiotic administration
Fujii 1987   •   •      
Three days versus 10 days of oral therapy
Table 1.   Reported outcomes of included studies  (Continued)
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A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL #1 PYELONEPHRITIS* explode all trees
#2 pyelonephritis
#3 URINARY TRACT INFECTIONS explode all trees
#4 urinary next tract next infection*
#5 kidney next infection*
#6 #1 or #2 or #3 or #4 or #5
#7 CHILD explode all trees
#8 #6 and #7
#9 ADULT explode all trees
#10 #8 not #9
MEDLINE 1. pyelonephritis/
2. urinary tract infections/
3. UTI.tw.
4. urinary tract infection$.tw.
5. pyelonephritis.tw.
6. or/1-5
7. exp antibiotics/
8. antibiotic treatment.tw.
9. antibiotic therap$.tw.
10. antibiotic$.tw.
11. or/7-10
12. 6 and 11
13. limit 12 to all child <0 to 18 years>
EMBASE 1. exp pyelonephritis/
2. urinary tract infection/
3. UTI.tw.
4. urinary tract infection$.tw.
5. pyelonephritis.tw.
6. or/1-5
7. exp antibiotic agent/
8. antibiotic therapy/
9. antibiotic treatment.tw.
10. antibiotic therap$.tw.
11. antibiotic$.tw.
12. or/7-11
13. 6 and 12
14. exp child/
15. exp adolescent/
16. 14 or 15
17. 13 and 16
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Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
  (Continued)
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substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Selective reporting
Reporting bias due to selective
outcome reporting
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other sources of bias.
High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
10 July 2014 New search has been performed New search, new studies included
10 July 2014 New citation required and conclusions
have changed
New studies included
 
H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 3, 2003
 
Date Event Description
1 February 2010 Amended Minor correction of data for Analysis 1.3.2 - no change in summa-
ry estimate of effect
13 May 2009 Amended Contact details updated.
17 June 2008 Amended Converted to new review format.
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Date Event Description
20 October 2007 Amended Full study data for Monitini 2003 added
14 August 2007 New citation required and conclusions
have changed
Substantive amendment
5 February 2007 Amended Five new studies added
15 October 2004 Amended Two new studies added
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Entering data into RevMan; PB, EH, YS
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Risk of bias assessment has replaced the quality assessment checklist; methodology has been updated to be in line with current Cochrane
Collaboration guidelines.
N O T E S
Issue 3, 2010. Correction of data entered for Hoberman 1999 in Analysis 1.6.2 (Patients with kidney parenchymal damage on initial DMSA).
Data published in Issue 4, 2007 were 17/100 for oral therapy and 12/87 for IV then oral therapy. The correct numbers are 15/100 for oral
therapy and 11/87 for IV then oral therapy. There is no significant change in the summary estimate (Issue 4, 2007: RR 0.79, 95% CI 0.53 to
1.16; Issue 3, 2010: RR 0.77, 95% CI 0.53 to 1.11).
The authors wish to thank Dr Bodil Als-Nielsen for notifying us of this error.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Acute Disease;  Administration, Oral;  Anti-Bacterial Agents  [administration & dosage]  [*therapeutic use];  Drug Therapy, Combination; 
Injections, Intravenous;  Pyelonephritis  [*drug therapy];  Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Child; Humans; Infant
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